Back grey_arrow_rt.gif
 
Latest articles on Hepatitis B.
 
null.gif
 
 
  1. IAC: Efficacy and Safety of Dolutegravir (DTG) in Hepatitis (HBV or HCV) Co-infected Patients: Results From the Phase 3 Program - (07/28/14)
     
  2. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: Virological and clinical implications - (07/16/14)
     
  3. Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis BA Nationwide Cohort Study - (07/16/14)
     
  4. Averting Hepatocellular Carcinoma in Chronic Hepatitis B With Antiviral Therapy: Tipping the Balance or Not Yet? - (07/16/14)
     
  5. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14)
     
  6. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection - (05/15/14)
     
  7. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA - (05/05/14)
     
  8. EASL: ADDING PEGINTERFERON TO ENTECAVIR INCREASES RESPONSE RATES IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS: WEEK 96 RESULTS OF A GLOBAL MULTICENTER RANDOMISED TRIAL (ARES STUDY) - (05/01/14)
     
  9. EASL: Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study: The NEED study - (05/01/14)
     
  10. EASL: Response-Guided Peginterferon Alfa-2a (PegIFN Alfa-2a) Therapy in Patients with HBeAg-Positive Chronic Hepatitis B (CHB) - (05/01/14)
     
  11. EASL: EFFECTIVENESS OF TENOFOVIR FOR CHRONIC HEPATITIS B IN FIELD PRACTICE - (04/30/14)
     
  12. EASL: Nucleos(t)ide Analogue (NA) Therapy for Persons in the Immunotolerant Phase of CHB Is Associated With Significant Declines in HBeAg and HBsAg Levels - (04/30/14)
     
  13. EASL: THE EFFICACY OF ENTECAVIR IN BOTH NAIVE AND LAMIVUDINE EXPERIENCED WITHOUT RESISTANCE CHRONIC HEPATITIS B PATIENTS - (04/30/14)
     
  14. EASL: ENTECAVIR AND TENOFOVIR HAVE A COMPARABLE EFFICACY IN TREATMENT OF NUCLEOS(T)IDE ANALOGUE NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A REAL LIFE EXPERIENCE - (04/30/14)
     
  15. EASL: RANDOMIZED TRIAL OF TENOFOVIR MONOTHERAPY VERSUS TENOFOVIR PLUS ENTECAVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B PATIENTS WITH GENOTYPIC RESISTANCE MUTATIONS TO ADEFOVIR - (04/30/14)
     
  16. EASL: LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY - (04/30/14)
     
  17. EASL: LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP) - (04/30/14)
     
  18. EASL: Determinants of Variability in ISG15 Gene Expression in Patients With Chronic Hepatitis B (CHB) Infection During Treatment With Oral TLR-7 Agonist GS-9620 - (04/28/14)
     
  19. EASL: Peginterferon Lambda for the Treatment of Chronic Hepatitis B (CHB): A Phase 2b Comparison With Peginterferon Alfa in Patients With HBeAg-Positive Disease (LIRA-B) - (04/21/14)
     
  20. EASL: REDUCED INCIDENCE OF HEPATOCELLULAR CARCINOMA IN HIV/HBV-COINFECTED PATIENTS RECEIVING TENOFOVIR - (04/21/14)
     
  21. APASL: Twenty-Eight Day Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B Patients - (03/19/14)
     
  22. Hepatitis B Screening - U.S. Preventive Services Task Force New Draft Recommendation Statement - (02/14/14)
     
  23. Potential Benefit of Telbivudine on Renal Function Does Not Outweigh Its High Rate of Antiviral Drug Resistance and Other Adverse Effects - Editorial - (01/17/13)
     
  24. Management of Hepatitis B: Our Practice and How It Relates to the Guidelines - (01/16/13)
     
  25. hepDART: Efficient Hepatic Delivery of Tenofovir by Prodrug Tenofovir Alafenamide in Nonclinical Studies Supports Low-Dose Treatment of Hepatitis B Virus (12/20/11)
     
  26. AASLD: Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies - (12/04/13)
     
  27. AASLD: Sustained Immune Control in HBeAg-Positive Chronic Hepatitis B Patients Who Switched From Long-Term Entecavir Therapy to Peginterferon Alfa-2a (40KD): 1-Year Follow-Up of the OSST Study - (11/25/13)
     
  28. AASLD: Entecavir Plus Tenofovir Combination Therapy in Patients with Multi-drug Resistant Chronic Hepatitis B - A multicenter, Prospective Study - Early Experience - (11/25/13)
     
  29. AASLD: Sustained Immune Control in HBeAg-Positive Chronic Hepatitis B Patients Who Switched From Long-Term Entecavir Therapy to Peginterferon Alfa-2a (40KD): 1-Year Follow-Up of the OSST Study - (11/25/13)
     
  30. AASLD: Shifting scales: comparing viral hepatits and HIV/AIDS mortality in the Global Burden of Disease Study 2010 - (11/20/13)
     
  31. AASLD: Virologic Response to Boceprevir Plus Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-naive Patients with Chronic Hepatitis C and HCV Genotype 1 Infection: Interim Analysis of Data From the International TriCo Study - (11/20/13)
     
  32. AASLD: Outcome of Treatment with Peginterferon alfa-2a (40KD) in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB) in the Real-World: Interim Analysis of Data from the Large European S-Collate Cohort - (11/20/13)
     
  33. AASLD: Morphometric Assessment of Quantitative Collagen and Liver Fibrosis in Patients With Chronic Hepatitis B Treated for Up to Five Years With Tenofovir Disoproxil Fumarate (TDF) - (11/19/13)
     
  34. AASLD: Seven Years of Treatment With Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance - (11/19/13)
     
  35. AASLD: Long Term Nucleo(t)ide Treatment (entecavir, lamivudine) Reduces Mortality in Chronic Hepatitis B Patients - (11/19/13)
     
  36. AASLD: Twenty-Eight Day Safety and Efficacy of Tenofovir Alafenamide (TAF) Fumarate in Chronic Hepatitis B (CHB) Patients - (11/18/13)
     
  37. AASLD: Hepatitis B Virus Screening and Prevalence in US Veterans in Department of Veterans Affairs Care - (11/16/13)
     
  38. AASLD: Safety, Tolerability, and Immunogenicity of GS-4774, an HBV-Specific Therapeutic Vaccine, in Healthy Volunteers - (11/14/13)
     
  39. EACS: 'Acute HCV BUT No HBV Reported' - Reports of Viral Hepatitis B and C in HIV Patients Participating in Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF and Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF - (10/21/13)
     
  40. EACS: Bristol-Myers Squibb Launches Initiative to support search for a cure in chronic viral diseases (HIV/HBV/HCV) - (10/16/13)
     
  41. IDSA: Entecavir Versus Tenofovir in Treatment-Naive Chronic Hepatitis B Patients: Third Year Results of a Real World Study - (10/11/13)
     
  42. New York State Updated HBV Guidelines in HIV+ - (08/30/13)
     
  43. Regression of Cirrhosis With Long-Term Tenofovir Treatment - (07/31/13)
     
  44. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection; Does Hepatitis B Treatment Reduce the Incidence of Hepatocellular Carcinoma? Editorial - (07/22/13)
     
  45. APASL: Hepatitis B Virus Infection in Western Region of China - (07/01/13)
     
  46. Targeting Innate HBV Immunity: A New Step in the Development of Combination Therapy for Chronic Hepatitis B; GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees - (06/26/13)
     
  47. HCV & HBV Therapy Reverses Fibrosis & Cirrhosis, several studies in HCV monoinfection, HCV/HIV coinfection & in HBV - (06/23/13)
     
  48. APASL: No Detectable Tenofovir Resistance With Tenofovir Disoproxil Fumarate (TDF) or TDF+Emtricitabine (FTC/TDF) Through 96 Weeks in Lamivudine-Resistant CHB Patients - (06/19/13)
     
  49. APASL: Six Years of Treatment With Tenofovir DF for Chronic Hepatitis B Virus Infection is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance - (06/19/13)
     
  50. APASL: 48 Weeks TDF Treatment Results in Potent Viral Suppression and A Favorable Safety Profile in Chinese Chronic Hepatitis B Patients - (06/19/13)
     
  51. APASL: Tenofovir Disoproxil Fumarate (TDF) in Asian Patients With High Baseline HBV-DNA Viral Load (HBV DNA ≥9 log10 copies/mL) - (06/19/13)
     
  52. APASL: High Prevalence of Vitamin D Deficiency Among Chronic Hepatitis B Patients Entering a Large Global Prospective Trial (Study GS-US-174-0149) - (06/19/13)
     
  53. APASL: Chronic Hepatitis B Treatment With Tenofovir DF (TDF): 2-Year Efficacy and Safety Results in a Real-Life Cohort - (06/19/13)
     
  54. APASL: Regression of Cirrhosis After HBsAg Seroconversion in a Cirrhotic 38 Year-Old Bangladeshi Man Treated with Tenofovir Disoproxil Fumarate - (06/19/13)
     
  55. APASL: HBsAg level predicts sustained response in peginterferon alfa-2a (40KD)-treated HBeAg-positive patients: initial post-treatment results from the 'real-life' S-Collate cohort - (06/17/13)
     
  56. APASL: Early on-treatment HBsAg level predicts response in HBeAg-positive chronic hepatitis B patients switched from long-term entecavir to peginterferon alfa-2a (40KD) - (06/17/13)
     
  57. APASL: The Relative Disease Burden of Viral Hepatitis C: A Comparison with Viral Hepatitis B - (06/17/13)
     
  58. APASL: Peginterferon Lambda for the Treatment of HBeAg-Positive Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa - (06/14/13)
     
  59. APASL: No Detectable Tenofovir Resistance With Tenofovir Disoproxil Fumarate (TDF) or TDF+Emtricitabine (FTC/TDF) Through 96 Weeks in Lamivudine-Resistant CHB Patients - (06/12/13)
     
  60. APASL: Efficacy and Safety of Tenofovir DF (TDF) in Chronic Hepatitis B Virus Infected Patients With Documented Lamivudine Resistance (LAM-R) - (06/12/13)
     
  61. Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV-Coinfected Adults With Persistent HBV Viremia - (05/30/13)
     
  62. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection - (05/25/13)
     
  63. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score - (05/25/13)
     
  64. (HBV) Risk score (REACH-B) for development of HCC: ready for use in practice? - (05/25/13)
     
  65. Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients - (05/25/13)
     
  66. Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment - (05/25/13)
     
  67. EASL: 5-year Entecavir treatment in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics - (05/15/13)
     
  68. EASL: Liver Disease in HBV-HIV Coinfection- Significant Fibrosis is Present Despite HBV Suppression and Anti-Retroviral Therapy - (05/15/13)
     
  69. EASL: Virological Response Does Not Lower Liver Disease Progression Among Chronic Hepatitis B Cirrhotic Patients Treated with Long-Term Nucleo(t)ide-Analogue - (05/15/13)
     
  70. EASL: INCIDENCE AND CLINICAL CONSEQUENCES OF REDUCED TUBULAR PHOSPHATE REABSORPTION IN NAIVE CHB PATIENTS TREATED WITH TENOFOVIR: A TWO-YEAR FIELD STUDY - (05/15/13)
     
  71. EASL: HARPE Study: Prevalence of Renal Abnormalities in Chronic Hepatitis B Virus Infection - (05/15/13)
     
  72. EASL: FROM COMBINATION-THERAPY TO MONO-THERAPY IN TREATMENT EXPERIENCED CHB PATIENTS WITH VIRAL RISISTENCE OR PARTIAL RESPONSES: FIRST RESULTS OF AN INTERNATIONAL MULTICENTER COHORT STUDY - (05/15/13)
     
  73. EASL: Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study - (05/15/13)
     
  74. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection - (05/13/13)
     
  75. EASL: Efficacy and Safety of Peginterferon Alfa-2a (40KD) in HBeAg-Positive Chronic Hepatitis B PatientsParticipating in a Response-Guided Therapy Study: An Interim Analysis at Week 72 - (05/09/13)
     
  76. EASL: S-collate cohort 'real-life' study: efficacy and safety of peginterferon alfa-2a (40KD) in 1233 patients with chronic hepatitis B according to Asian and Caucasian race - (05/09/13)
     
  77. EASL: Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients - (05/08/13)
     
  78. EASL: Long-term Tenofovir Disoproxil Fumarate (TDF) Therapy and the Risk of Hepatocellular Carcinoma - (05/08/13)
     
  79. EASL: Tenofovir Disoproxil Fumarate in Chronic HBV Patients With Normal ALT Levels and High HBV DNA Levels, also titled: TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUS-INFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE - (05/08/13)
     
  80. EASL: Comparison of Serum HBsAgDeclines During Tenofovir Disoproxil Fumarate (TDF) Treatment in Different Chronic Hepatitis B (CHB) Patient Populations - (05/08/13)
     
  81. EASL: HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBE-) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HEPNET.GREECE COHORT STUDY - (05/08/13)
     
  82. EASL: ALT Flares During Treatment with Peginterferon Lambda-1a or Peginterferon Alfa in Patients With HBeAg-positive Chronic Hepatitis B Infection (CHB) - (05/08/13)
     
  83. EASL: IMPROVED HBsAgLOSS RATE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PROLONGED PEGINTERFERON α-2A COMBINED WITH NUCLEOS(T)IDE ANALOGUE - (05/08/13)
     
  84. EASL: Tenofovir Disoproxil Fumarate (TDF) Is Safe and Well Tolerated in Chronic Hepatitis B (CHB) Patients With Pre-Existing Mild Renal Impairment - (05/08/13)
     
  85. CROI: Protective Effect of HBV-active c-ART against primary HBV-Infection - (03/05/13)
     
  86. Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses - (02/19/13)
     
  87. GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus (and HCV) in Chronically Infected Chimpanzees - (02/19/13)
     
  88. Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis - (02/19/13)
     
  89. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis - (01/25/13)
     
  90. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study - & Commentary....."long-term suppression of HBV can lead to regression of fibrosis and cirrhosis....." - (01/12/13)
     
  91. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort (ACTG) - (12/20/12)
     
  92. AASLD: Chronic hepatitis B patients with advanced fibrosis/compensated cirrhosis can benefit from peginterferon alfa-2a (40KD): improved or comparable response rates versus mild fibrosis in the phase III studies - (11/26/12)
     
  93. AASLD: New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a (40 kD) induces HBeAg seroconversion/HBsAgloss in patients with HBeAg-positive chronic hepatitis B (The OSST study) - (11/19/12)
     
  94. AASLD: Six Years of Treatment With Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance - (11/19/12)
     
  95. AASLD: Antiviral Efficacy of Entecavir in Black/African American and Hispanic Patients with Chronic Hepatitis B who are Nucleos(t)ide Naïve - (11/19/12)
     
  96. AASLD: SWITCHING TO TENOFOVIR IS SAFE IN MOST CHRONIC HEPATITIS B PATIENTS WITH A REDUCED GLOMERULAR FILTRATION RATE DUE TO PREVIOUS EXPOSURE TO ADEFOVIR DIPIVOXIL - (11/19/12)
     
  97. AASLD: Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment - (11/19/12)
     
  98. AASLD: Tenofovir monotherapy suppressed viral replication in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study - (11/19/12)
     
  99. AASLD: Nucleos(t)ide analogues can be safely discontinued in CHB patients achieving HBsAgclearance - (11/19/12)
     
  100. U.S. Food and Drug Administration Approves Labeling Update for BARACLUDE® (entecavir) (0.5 mg/1 mg Tablets) to Include Data on African Americans and Liver Transplant Recipients with Chronic Hepatitis B in Adult Patients - (10/16/12)
     
  101. ICAAC: Tenofovir Replacing AZT of ABC, Keeping 3TC, Suppresses HBV DNA - written by Mark Mascolini - (09/11/12)
     
  102. Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B - (08/28/12)
     
  103. The patient, the doctor, and the system: Underdiagnosis and undertreatment of hepatitis B - (08/23/12)
     
  104. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Renal function improves with long-term telbivudine therapy in patients with chronic hepatitis B Analysis of the Clinical data Base - (08/20/12)
     
  105. Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence- 1 in 5 were tested for HBV infection and 1 of 8 for HCV infection in 4 US HCOs - (08/17/12)
     
  106. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection 2012 - (07/18/12)
     
  107. Hepatitis B in the united states: a major health disparity affecting many foreign-born populations - (06/03/12)
     
  108. EASL: Response-guided peginterferon alfa-2a therapy based on HBsAglevels at week 12 and week 24 or 48 improves response rates in HBeAg-negative, genotype D patients - (05/10/12)
     
  109. EASL: Improved predictive value for sustained immune control in peginterferon (PEGASYS)-treated HBeAg-positive patients using combined HBsAgand HBV DNA levels at week 24 - (05/10/12)
     
  110. EASL: Relationship between Precore / Core Promoter Mutants, HBeAg levels and Serological Response in HBeAg-Positive Chronic Hepatitis B Patients treated with Nucleos(t)ide Analogues 2 - (05/08/12)
     
  111. EASL: Relationship between precore / core promoter mutants, HBeAg levels and serological response in HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues - (05/07/12)
     
  112. EASL: Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B - (05/07/12)
     
  113. EASL: OUTCOMES OF ENTECAVIR (ETV) AND TENOFOVIR (TDF) COMBINATION THERAPY IN CHRONIC HEP-B PATIENTS WITH PREVIOUS TREATMENT FAILURE - (05/04/12)
     
  114. EASL: Safety and Efficacy of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B - (05/04/12)
     
  115. EASL: Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months - (05/04/12)
     
  116. EASL: Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B : a 4-year field practice, multicenter study - (05/04/12)
     
  117. Natural history of chronic hepatitis B: what exactly has REVEAL Revealed? "Serum HBV DNA level was identified as the most important risk predictor for progressing to end-stage liver disease outcomes" - (04/30/12)
     
  118. High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load: "in patients with HBV DNA level <2000 IU/mL who had a similar risk of HCC, HBsAglevel ≥1000 IU/mL was identified as a new independent risk factor for HCC development. These data suggested that HBsAglevel might complement HBV DNA level in predicting HCC development, especially in the lowly viremic HBV carriers" - (04/30/12)
     
  119. Identifying Hepatitis B Carriers at Low Risk for Hepatocellular Carcinoma - editorial - (04/30/12)
     
  120. APASL: Early HBsAgdecline as a predictor of HBsAgclearance in 'real life': results of the S-Collate cohort study in683 HBeAg-negative patients - (02/27/12)
     
  121. APASL: S-Collate cohort study: on-treatment HBsAglevel analysis in 'real-life' confirms prediction of response observed in NEPTUNE and phase III studies of peginterferon alfa-2a in HBeAg-positive patients - (02/27/12)
     
  122. APASL: Five Years of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Associated with Sustained Viral Suppression and Significant Regression of Fibrosis and Cirrhosis - (02/27/12)
     
  123. APASL: No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg- Chronic Hepatitis B Virus Infection - (02/27/12)
     
  124. APASL: Low Baseline Hepatitis B Surface Antigen (HBsAg) Levels and HBV Genotypes B/C are Associated with Persistently Low HBsAgin HBeAg+ Patients Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/27/12)
     
  125. APASL: Asians have Different Hepatitis B Surface Antigen (HBsAg) Kinetics than Non-Asians while Undergoing Treatment with Tenofovir Disoproxil Fumarate (TDF) or Adefovir (ADV) Followed by TDF up to 192 Weeks - (02/27/12)
     
  126. APASL: Hepatitis B Surface Antigen (HBsAg) Loss in HBeAg+ Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/25/12)
     
  127. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome - (02/03/12)
     
  128. HBV Viral Load is Associated with Risk for Liver Cancer (HCC) & HBV Disease Progression - (01/12/12)
     
  129. Preventing Deaths in Persons With HIV/Hepatitis B Virus Coinfection: A Call to Accelerate Prevention and Treatment Efforts - EDITORIAL - (01/02/12)
     
  130. Hepatitis B Virus Coinfection Negatively Impacts HIV Outcomes in HIV Seroconverters - (01/02/12)
     
  131. The Economic Cost of Advanced Liver Disease - (01/02/12)
     
  132. Hepatitis B (HBV) - (11/30/11)
     
  133. AASLD: Baseline and early on-treatment characteristics in HBeAg-positive patients with chronic hepatitis B infection achieving an early on-treatment response to pegylated interferon alfa-2a (40KD): interim results from the RGT study - (11/20/11)
     
  134. AASLD: Patients with HBeAg-positive chronic hepatitis B with a maintained virologic response to entecavirachieved HBsAgclearance when switched to peginterferon alfa-2a (40KD) therapy (the OSST study) - (11/16/11)
     
  135. AASLD: A novel combination regimen of peginterferon alfa-2a (40KD) and entecavir results in sustained post-treatment HBsAgclearance in HBeAg-positive chronic hepatitis B - (11/16/11)
     
  136. AASLD: Peginterferon alfa-2a monotherapy as a strategy for achieving sustained response in patientsswitched from long-term nucleos(t)ide analog therapy: the results of 1 year follow up - (11/16/11)
     
  137. AASLD: A response-guided approach to pegylated interferon alpha-2a (40KD) therapyto improve response rates in HBeAg-negative, genotype D patients - (11/16/11)
     
  138. AASLD: Response rates are similar for patients with and without advanced fibrosis/cirrhosis, and highest with peginterferon alfa-2a (40KD) 180 μg for 48 weeks in the NEPTUNE study - (11/16/11)
     
  139. AASLD: Five years of Treatment with Tenofovir DF for Chronic Hepatitis B Infection is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis - (11/14/11)
     
  140. AASLD: No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg-Chronic Hepatitis B Virus Infection - (11/14/11)
     
  141. AASLD: Five years of Treatment with Tenofovir DF for Chronic Hepatitis B Infection in Asian Patients is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis - (11/14/11)
     
  142. AASLD: Gilead Announces Positive Five-Year Data Showing Effect of Viread(R) on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B: '88% of patients on tenofovir in studies experienced reversal of fibrosis/cirrhosis' - press release - (11/14/11)
     
  143. AASLD: Disease burden in patients with chronic hepatitis C virus (HCV) infection in a United States (US) private health insurance claims database analysis from 2003 to 2010 - (11/10/11)
     
  144. AASLD: Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naïve patients with chronic hepatitis B (CHB): the BE-LOW study - (11/10/11)
     
  145. AASLD: Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms - press release - (11/10/11)
     
  146. Hepatitis delta in HIV-infected individuals in Europe - (09/07/11)
     
  147. Hepatitis B (HBV) - (06/17/11)
     
  148. Economic Analysis of Hepatitis B Screening and Treatment - Editorial - (06/01/11)
     
  149. The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States - (06/01/11)
     
  150. ENTECAVIR TREATMENT FOR CHRONIC HEPATITIS B: ADAPTATION IS NOT NEEDED FOR THE MAJORITY OF NAïVE PATIENTS WITH A PARTIAL VIROLOGICAL RESPONSE - (05/23/11)
     
  151. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients - (05/09/11)
     
  152. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogs in clinical practice - pdf attached - (05/04/11)
     
  153. EASL: Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA) Assessments in Patients with Chronic Hepatitis B (CHB) - (04/18/11)
     
  154. EASL: Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies - (04/18/11)
     
  155. EASL: NEPTUNE STUDY: ON-TREATMENT HBsAgLEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBeAg-POSITIVE PATIENTS - (04/13/11)
     
  156. EASL: Baseline Genotype And HBsAgWere Found To Have Significant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment - (04/13/11)
     
  157. EASL: Highest Rates of Response at Week 72 of the NEPTUNE Study are Achieved with Peginterferon Alfa-2a 180 μg for 48 weeks - (04/13/11)
     
  158. EASL: Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees - (04/07/11)
     
  159. EASL: Anti-Viral Efficacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection - (04/07/11)
     
  160. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues - (03/29/11)
     
  161. CROI: Fibrosis Predicts Renal Trouble With Tenofovir in HIV/HBV-Coinfected - written by Mark Mascolini - (03/8/11)
     
  162. APASL: Efficacy and Safety of Entecavir Treatment in a Heterogeneous CHB Population in a Real-Life Setting in China - (02/24/11)
     
  163. APASL: Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation: Week 96 Results - (02/24/11)
     
  164. APASL: No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus - (02/23/11)
     
  165. APASL: HBV rtN236T Mutant Subpopulations Respond Like Wild-Type During Tenofovir DF (TDF) Monotherapy or Combination Therapy with Emtricitabine (FTC) - (02/21/11)
     
  166. APASL: Four Year Efficacy and Safety of Tenofovir DF in HBeAg-Negative and HBeAg-Positive Patients with Chronic Hepatitis B (CHB) - (02/21/11)
     
  167. APASL: Tenofovir Disoproxil Fumurate (TDF) Demonstrates Good Efficacy and Safety in Asians with Chronic Hepatitis B (CHB) in Real-Life Settings - (02/21/11)
     
  168. APASL: Tenofovir Disoproxil Fumurate (TDF) Shows Similar Virologic Suppression and Safety between Asians and Non-Asians with Chronic Hepatitis B (CHB) - (02/21/11)
     
  169. APASL: Treatment patterns for hepatocellular carcinoma (HCC) in China: findings from the global HCC BRIDGE study - (02/21/11)
     
  170. APASL: Recent trends in hepatocellular carcinoma (HCC) practice in Taiwan: report from the global HCC BRIDGE study - (02/21/11)
     
  171. APASL: Response rates with shorter duration and lower doses of peginterferon alfa-2a are inferior to those with 180 μg for 48 weeks - (02/21/11)
     
  172. APASL: Peginterferon alfa-2a (180 μg/48 weeks) is well tolerated with high rates of treatment adherence: results of the NEPTUNE study - (02/21/11)
     
  173. APASL: Multicenter Evaluation of the Elecsys® HBsAgII Quant Assay - (02/21/11)
     
  174. Study of adherence comes to the treatment of chronic hepatitis B - (02/14/11)
     
  175. Association Between the Various Mutations in Viral Core Promoter Region to Different Stages of Hepatitis B, Ranging of Asymptomatic Carrier State to Hepatocellular Carcinoma - pdf atached - (02/14/11)
     
  176. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure - pdf attached - (02/14/11)
     
  177. Editorial: Viral Factors and Outcomes of Chronic HBV Infection - (02/14/11)
     
  178. A Simulation Shows That Early Treatment Of Chronic Hepatitis B Infection Can Cut Deaths And Be Cost-Effective - pdf attached - (02/11/11)
     
  179. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease - pdf attached - (01/16/11)
     
  180. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus - published pdf attached - (01/03/11)
     
  181. SF HBV Test/Treat Program - Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic - published pdf attached - (12/30/10)
     
  182. Is chronic hepatitis B being undertreated in the United States? - published pdf attached - (12/19/10)
     
  183. AASLD: Gilead's New HCV Drugs Studies & HBV at AASLD - (11/15/10)
     
  184. AASLD: Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103) - (11/04/10)
     
  185. AASLD: Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/04/10)
     
  186. AASLD: Viread(R) for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment - (11/29/10)
     
  187. AASLD: Efficacy and Safety of Entecavir in Nucleos(t)ide Naïve Asians With HBeAg-Positive and -Negative Chronic Hepatitis B: Results from Studies ETV-022/027 - (11/21/10)
     
  188. AASLD: Long-term Entecavir Treatment for Up to 5 Years in Asians With HBeAg-positive Chronic Hepatitis B: Results From ETV-022 and -901 - (11/21/10)
     
  189. AASLD: Effectiveness and safety of Tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B - (11/21/10)
     
  190. AASLD: Safety Findings From S-Collate, A Large, Multinational, Non-Interventional Cohort Study Of Patients With Chronic Hepatitis B Infection Treated With Peginterferon Alfa-2a [40kd] - (11/21/10)
     
  191. AASLD: Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience - (11/21/10)
     
  192. AASLD: Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40KD] in genotype D patients with HBeAg-negative chronic hepatitis B - (11/21/10)
     
  193. AASLD: Changes In HBsAgLevels Among Patients With Chronic Hepatitis B Treated With Peginterferon Alfa-2a [40kd] Enrolled In The S-Collate Cohort Study - (11/21/10)
     
  194. AASLD: Changes In HBeAg Levels Among Patients With HBeAg-Positive Chronic Hepatitis B Treated With Peginterferon Alfa-2a [40KD] Enrolled In The S-Collate Cohort Study - (11/21/10)
     
  195. AASLD: Effectiveness and safety of Tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B - (11/15/10)
     
  196. AASLD: No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus - (11/08/10)
     
  197. AASLD: Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 µg: NEPTUNE study - (11/08/10)
     
  198. Virologic and Clinical Outcomes in HIV/HBV Coinfected Patients on Tenofovir-Containing HAART - pdf attached - (10/27/10)
     
  199. Long-Term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus - pdf attached - (10/27/10)
     
  200. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B - pdf attached - (10/27/10)
     
  201. Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection - pdf attached - (10/27/10)
     
  202. Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-Analyses - pdf published attached - (08/25/10)
     
  203. HBV Drug Therapy: Tenofovir....IFN, Entecavir publication pdf attached - (08/11/10)
     
  204. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients - publication pdf attached - (08/11/10)
     
  205. HBV infection as a risk factor for non-Hodgkin lymphoma - Comment - (08/06/10)
     
  206. Chronic HBV Raises Lymphoma Risk - full text of published article below & pdf attached of published study - (08/06/10)
     
  207. HBV Viral Load/Fibrosis/ALT/Inflammation HBeAg+/HBeAg-: "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B" - (08/06/10)
     
  208. HBV infection as a risk factor for non-Hodgkin lymphoma - Comment - (08/06/10)
     
  209. Chronic HBV Raises Lymphoma Risk - full text of published article below & pdf attached of published study - (08/06/10)
     
  210. HBV Viral Load/Fibrosis/ALT/Inflammation HBeAg+/HBeAg-: "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B" - (08/06/10)
     
  211. HBV Antiviral Therapy in HCC Can Prevent Death & Transplant - (06/30/10)
     
  212. Intrn Wrkshp Pharm Hep Therapy: A European Perspective: EMA and his critical standpoint, Prof. Jean-Michel Pawlotsky, MD, PhD - (07/23/10)
     
  213. The Prevalence of Hepatitis B Virus Infection in the United States in the Era of Vaccination - (06/20/10)
     
  214. EASL: Evaluation of Potential Virologic Resistance in HBV Polymerase Among Subjects with Persistent Viremia Following up to 144 Weeks of Therapy with Tenofovir DF - (04/22/10)
     
  215. EASL: HBsAgKinetics of Decay and Baseline Characteristics of HBeAg-Positive Patients with Chronic Hepatitis B Following 3 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment - (04/22/10)
     
  216. EASL: From Ash To Cure - EASL April 14-18 2010 - (04/21/10)
     
  217. EASL: Efficacy of Tenofovir DF Treatment in Patients with a Suboptimal Response to Adefovir Dipivoxil - (04/21/10)
     
  218. EASL: Risk and Predictors of Mortality or Hepatocellular Carcinoma among Entecavir- or Adefovir-Treated Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (04/21/10)
     
  219. EASL: Low Rates of Nucleos(t)ide-associated Adverse Events in the Long-term Experience with Entecavir - (04/21/10)
     
  220. A new role for an old marker, HBsAg - (04/07/10)
     
  221. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia - (04/07/10)
     
  222. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective - (04/07/10)
     
  223. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection - The current long-term study of entecavir presents results for a cohort of patients treated continuously for 3years. - (03/31/10)
     
  224. APASL: Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] (PEGASYS) plus lamivudine or adefovir for 96 weeks results in high rates of HBsAgclearance / seroconversion - (03/31/10)
     
  225. APASL: Identification of a baseline algorithm to select chronic hepatitis B patients for therapy with peginterferon alfa-2a [40KD] (PEGASYS) - (03/31/10)
     
  226. APASL: A pilot study of interferon alpha/peginterferon alfa-2a combined with response-guided short-term nucleoside analog therapy in HBeAg-positive hepatitis B patients - (03/31/10)
     
  227. APASL: Tenofovir 3- Year Efficacy, Safety and Resistance - Treatment in HBeAg Positive and Negative Patients with Chronic Hepatitis B - (03/31/10)
     
  228. APASL: 3 Years Efficacy and Safety of Tenofovir in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B - (03/31/10)
     
  229. APASL: Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (03/31/10)
     
  230. APASL: The Antiviral Effects and Safety of Entecavir Versus Lamivudine Treatment in Nucleos(t)ide-naïve HBeAg-negative Korean Chronic Hepatitis B Patients: Week 48 Interim Analysis - (03/31/10)
     
  231. APASL: On-Treatment Decline in Serum HBsAgLevels Predicts Sustained Immune Control 1 Year Post-Treatment and Subsequent HBsAgClearance in HBeAg-Negative Hepatitis B Virus-Infected Patients Treated with Peginterferon Alfa-2a [40KD] (PEGASYS) - (03/31/10)
     
  232. APASL: On-Treatment Decline in Serum HBsAgLevels Predicts Sustained Immune Control and HBsAgClearance 6 Months Post-Treatment in HBeAg-Positive Hepatitis B Virus-Infected Patients Treated with Peginterferon Alfa-2a [40KD] (PEGASYS) - (03/31/10)
     
  233. APASL: Sustained Immune Control 1 Year Post-Treatment with Peginterferon Alfa-2a [40KD] (PEGASYS) is Durable up to 5 Years Post-Treatment and is Associated with a High Rate of HBsAgClearance in HBeAg-Negative Chronic Hepatitis B - (03/31/10)
     
  234. APASL: Large International, Observational Study of Patients with Chronic Hepatitis B Infection Treated with Peginterferon Alfa-2a [40KD] (PEGASYS): the S-Collate Cohort - (03/31/10)
     
  235. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus - (03/19/10)
     
  236. CROI: Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus - (03/04/10)
     
  237. CROI: Positive HBV Vaccine Response Halves HIV Progression and Death Risk in US Military - written by Mark Mascolini - (02/25/10)
     
  238. Longer HAART (tenofovir) Use Predicts Hepatitis B Clearance - (02/04/10)
     
  239. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease - (01/26/10)
     
  240. HCV & HBV Medican/Medicare Training by NYS DOH - (01/26/10)
     
  241. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis - (01/21/10)
     
  242. Liver cancer: From molecular pathogenesis to new therapies: Summary of the EASL single topic conference - (01/21/10)
     
  243. Entecavir in decompensated HBV cirrhosis: The future is looking brighter - (01/20/10)
     
  244. Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years - (01/17/09)
     
  245. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B - (01/11/10)
     
  246. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues - (01/06/10)
     
  247. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety - (01/06/10)
     
  248. AASLD: Parenchymal Fibrosis and Cancer Specific Outcomes Following Liver Resection in Patients with HBV Associated Hepatocellular Carcinoma - (12/10/09)
     
  249. AASLD: Prevalence and Characteristics of Hepatitis B Virus Mutations in Chronic Hepatitis B Patients on Oral Antiviral Therapy: The CHARM Study - (12/07/09)
     
  250. AASLD: Higher Sustained Post-Treatment Virologic Response Following Peginterferon Alfa-2a ± Adefovir Compared With Adefovir Monotherapy in HBeAg-Positive Patients - (12/02/09)
     
  251. AASLD: Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (12/02/09)
     
  252. AASLD: Diagnosis and Management of Chronic Hepatitis B in Asian-American Patients Among Primary Care Physicians in the United States - (12/02/09)
     
  253. AASLD: Adherence to AASLD Guideline Recommendations for Laboratory Monitoring of Chronic Hepatitis B Patients Who are Not Receiving Antiviral Treatment - (12/02/09)
     
  254. AASLD:HBsAgDecline in HBeAg-Negative Patients Treated With Peginterferon Alfa-2a is Associated With Sustained Response up to 5 Years Post-Treatment: Patients with Continuous HBsAgDecline Starting Before Week 24 Achieve Highest Rates of Response - (12/01/09)
     
  255. AASLD: A Finite Course of Peginterferon Alfa-2a Results in Inactive Chronic Hepatitis B and HBsAgClearance 5 Years Post-Treatment in Patients With HBeAg-Negative Disease: Baseline Characteristics and Predictive Factors of Long-Term Response - (12/01/09)
     
  256. AASLD: HBsAgClearance Continues to Increase Post-Treatment in Patients with HCV/HBV Coinfection Treated With Peginterferon Alfa-2a Plus Ribavirin: 1.5 Year Follow up - (12/01/09)
     
  257. AASLD: Extended Treatment With Peginterferon Alfa-2a Benefits Patients With HBeAg-Positive Chronic Hepatitis B With a Partial Response After 48 Weeks of Therapy - Clinical Experience From a Chinese Center - (12/01/09)
     
  258. AASLD: Extending Peginterferon Alfa-2a Therapy in Patients With HBeAg-Positive Chronic Hepatitis B Who Did Not Achieve a Response at Week 48 Can Lead to HBeAg Seroconversion and HBsAgClearance - (12/01/09)
     
  259. AASLD: On-Treatment Quantification of HBsAgin Difficult-to-Treat Patients With Lamivudine Resistance Can Help Identify Those Most Likely to Achieve Sustained Post-Treatment Response to Peginterferon Alfa-2a Rescue Therapy - (12/01/09)
     
  260. AASLD: Physician Country of Birth and Hepatitis B Virus (HBV) Screening Practices of Asian-American Primary Care Providers (PCPs) Who Treat Asian Adults Living in the US - (11/30/09)
     
  261. AASLD: Tenofovir Disoproxil Fumarate-Containing Regimens in Pregnancy: Report From the Antiretroviral Pregnancy Registry - (11/30/09)
     
  262. AASLD: Resistance Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis B Patients Treated with Tenofovir DF Showed No Relationship Between Virologic Breakthrough and Emergence of Genotypic Changes in HBV Polymerase - (11/30/09)
     
  263. AASLD: Three Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B - (11/30/09)
     
  264. AASLD: In Vitro Tenofovir Sensitivity of HBV Populations from Clinical Specimens Containing rtA181T/V and/or rtN236T - (11/30/09)
     
  265. AASLD: TENOFOVIR (TDF) IS EFFECTIVE IN LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B PATIENTS WHO HARBOUR rtA194T AT BASELINE - (11/30/09)
     
  266. Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries - (11/25/09)
     
  267. Hepatitis B Virus Resistance to Nucleos(t)ide Analogues - (11/11/09)
     
  268. AASLD: Entecavir and Tenofovir combination therapy in chronic Hepatitis B: Rescue therapy in patients with advanced fibrosis and multiple previous treatment failures. Results from an international multicenter cohort study. - (11/10/09)
     
  269. AASLD: High rates of HBeAg seroconversion and HBsAgloss with Tenofovir + Emtricitabine in patients with HBV-HIV co-infection irrespective of CD4+ cell count - (11/10/09)
     
  270. AASLD: Loss of HBsAgin Nucleoside-Naïve HBeAg(+) Chronic Hepatitis B Patients Following Treatment with Entecavir or Lamivudine: Evaluation of HBV Genotypes - (11/10/09)
     
  271. AASLD: Long-term Follow-up Evaluation of the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in a European Multicenter (Nucleos(t)ide Experienced) Hepatitis B Virus HBV-infected Cohort - (11/10/09)
     
  272. AASLD: Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from a large multicenter cohort study in 376 patients - (11/10/09)
     
  273. AASLD: Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/06/09)
     
  274. AASLD: Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) With Chronic Hepatitis B (Study 103) - (11/06/09)
     
  275. AASLD: Resistance Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis B Patients Treated with Tenofovir DF Showed No Relationship Between Virologic Breakthrough and Emergence of Genotypic Changes in HBV Polymerase - (11/06/09)
     
  276. AASLD: A Phase 2, Double-Blind, Randomized Study Comparing The Safety of Tenofovir Disoproxil Fumarate (TDF), Emtricitabine Plus TDF (Truvada, TVD) and Entecavir (ETV) in Subjects with Decompensated Chronic Hepatitis B Liver Disease - (11/06/09)
     
  277. AASLD: Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States - (11/06/09)
     
  278. AASLD: HBsAgDecline in HBeAg-Negative Patients Treated With Peginterferon Alfa-2a is Associated With Sustained Response up to 5 Years Post-Treatment: Patients with Continuous HBsAgDecline Starting Before Week 24 Achieve Highest Rates of Response - (11/01/09)
     
  279. Rep Honda Introduces Bi-Partisan Bill to End Hepatitis Epidemic in America - (10/29/09)
     
  280. ICAAC: Acute HBV & HCV Infection Among MSM: CDC Data from Population-Based Surveillance, 2006-2008 - (09/25/09)
     
  281. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients - (09/11/09)
     
  282. Chronic hepatitis B: Update 2009 AASLD Guidelines - (09/11/09)
     
  283. Racial Differences in HBV Liver Transplant Linked to Underlying Disease - (09/03/09)
     
  284. Loss of HBsAgantigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B - (08/17/09)
     
  285. Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a - (06/26/09)
     
  286. HIV Resistance Wksp: HBV Resistance to Lamivudine at Undetectable and Low Levels of Viremia - written by Mark Mascolini - (06/15/09)
     
  287. DDW: Association between HBV Replication and Serum ALT Changes is not Dependent on HBV Genotype and Mutants - (06/08/09)
     
  288. DDW: Regression of Fibrosis/Cirrhosis with Long-Term Entecavir Therapy in Chronic Hepatitis B (CHB) Patients with Baseline Bridging Fibrosis or Cirrhosis: Results from Studies ETV-022, -027 and -901 - (06/08/09)
     
  289. DDW: Long-Term Histological Improvement with Entecavir (ETV) Therapy in Patients with Chronic Hepatitis B (CHB) from Japanese and Worldwide Development Programs - (06/08/09)
     
  290. DDW: Risk and Predictors of HCC in People Less than 40 years of Age: Update from the R.E.V.E.A.L.-HBV Study - (06/08/09)
     
  291. DDW: Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment - (06/08/09)
     
  292. DDW: Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients - (06/08/09)
     
  293. Hepatitis B antiviral drug resistance common but avoidable - by 'using tenofovir or entecavir firstline' - (06/05/09)
     
  294. CDC Updated Viral Hepatitis Surveillance - (06/05/09)
     
  295. Liver Cancer Rates Triple: Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 - (06/03/09)
     
  296. Clevudine myopathy in patients with chronic hepatitis B - (06/02/09)
     
  297. Benefits and risks of interferon therapy for hepatitis B Meeting Report Review Robert Perillo - (05/09/09)
     
  298. EASL: Evolution of Viral Load and Genome Sequence in a Clinical Trial of Tenofovir/Emtricitabine Combination Versus Tenofovir Monotherapy for Patients with Previous Adefovir Dipivoxil Failure - (05/07/09)
     
  299. EASL: Characteristics of HBeAg-Positive Patients with HBsAgLoss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF) - (05/07/09)
     
  300. EASL: Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients - (05/06/09)
     
  301. EASL: Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB) - (05/06/09)
     
  302. EASL: Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil - (05/06/09)
     
  303. EASL: BASELINE HBsAgLEVEL PREDICT HBsAgLOSS IN CHRONIC HEPATITIS B PATIENTS TREATED WITH A COMBINATION OF PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS - (05/06/09)
     
  304. EASL: HBsAgDecline Appears To Predict Clearance- Increasing Rates of HBsAgClearance and Seroconversion in Patients With HBeAg-Negative Disease Treated With Peginterferon Alfa-2a ± Lamivudine: Results of 5-Year Post-Treatment Follow-up - (05/06/09)
     
  305. EASL: Hepatitis B Virus Drugs in Pregnancy: Findings from the Antiretroviral Pregnancy Registry - (05/06/09)
     
  306. EASL: On-Treatment Monitoring of HBsAgLevels to Predict Response to Peginterferon Alfa-2a in Patients With HBeAg-Positive Chronic Hepatitis B - (05/05/09)
     
  307. EASL: Tenofovir 2 Years Safety, Efficacy & Resistance in Patients with Cirrhosis - (05/01/09)
     
  308. EASL: Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naive Patients - (04/29/09)
     
  309. EASL: Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment - (04/29/09)
     
  310. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients - (04/22/09)
     
  311. Celsion Receives Orphan Drug Designation for ThermoDox to Treat Primary Liver Cancer - (04/20/09)
     
  312. Researchers Uncover Low-Frequency Hepatitis B Drug-Resistant Mutations Using 454 Sequencing Systems - (04/08/09)
     
  313. Ultra-Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse-Transcriptase Inhibitor (NRTI)-Treated Patients and NRTI-Naive Patients - (04/08/09)
     
  314. Early serum HBsAgdrop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients - (04/06/09)
     
  315. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B - (04/06/09)
     
  316. Hepatitis B surface antigen quantification as a current-day paradox: Obtaining the gold in the face of diminishing returns - Editorial - (04/06/09)
     
  317. Preventing HCC by HBV Treatment - (04/06/09)
     
  318. Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses - (04/02/09)
     
  319. Treatment of HBV/HCV Coinfection: Releasing the Enemy Within - (04/02/09)
     
  320. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening - (03/30/09)
     
  321. EHDRW: Minority Clusters of K103N Mutation in Antiretroviral-Naive People in B & non-B Subtypes - Written by Mark Mascolini (03/27/09)
     
  322. ISHLVD: Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD - (03/27/09)
     
  323. ISHLVD: Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901 - (03/26/09)
     
  324. ISHLVD: Five-Years of Continuous Entecavir for Nucleoside-Naive HBeAg(+) Chronic Hepatitis B: Results from Studies ETV-022/-901 - (03/26/09)
     
  325. ISHLVD: Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 103) - (03/26/09)
     
  326. ISHLVD: Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (03/26/09)
     
  327. ISHLVD: Telaprevir (TVR, T) q8h or q12h Combined With Either Peginterferon (PEG-IFN, P) Alfa-2a or Alfa-2b and Ribavirin (RBV, R) in Treatment-Naive Genotype 1 Hepatitis C: Week 12 Interim Results of the Randomized, Open-Label, Multicenter Phase 2 Study C208 - (03/26/09)
     
  328. ISHLVD: Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103 - (03/25/09)
     
  329. ISHLVD: Developing HBV/HCV Associated Liver Cancer At A Young Age < 40 Yrs Old - (03/25/09)
     
  330. ISHLVD: Study Reports Asain-Americans Not Getting Screened and Not Being Perceived As Being At Risk for HBV by Asian Primary Care Providers - (03/23/09)
     
  331. CROI: Review of HIV+ Patient's Immunological Response Rate to High-dose HBV Re-vaccination Series: Cd4 & viral load predict response - (03/17/09)
     
  332. CROI: Predictors of Chronic HBV Infection in HIV-infected Individuals: HAART Can Prevent Chronic HBV - (03/17/09)
     
  333. CROI: The Long-term Use of Tenofovir in HIV/HBV Co-infection Induces a Marked Decrease in Liver Fibrosis - (03/17/09)
     
  334. CROI: ART Reinitiation and HBV Rebound among HIV/HBV-co-infected Patients following ART Interruption in the Strategies for the Management of ART Study - (03/17/09)
     
  335. Eisai Announces Approval of Clevudine for the Treatment of Chronic Hepatitis B in the Philippines - (03/16/09)
     
  336. APASL: Quantitative HBsAgfor early prediction of response to PEGASYS therapy in patients with HBeAg-negative disease - (03/12/09)
     
  337. APASL: Histologic Assessment of Long-term Entecavir (ETV) Treatment in Chronic Hepatitis B (CHB) Patients - (03/12/09)
     
  338. APASL: HBsAgClearance Continues to Increase After the End of Treatment With PEGASYS ± Lamivudine: 5-year Follow-up Study in Patients with HBeAg-Negative Disease - (03/12/09)
     
  339. APASL: HBsAgDecline in Patients Treated With PEGASYS and its Association with Post-treatment Response in HBeAg-Positive Chronic Hepatitis B - (03/12/09)
     
  340. APASL: PEGASYS But Not Adefovir Results in Significant Decline in HBsAgin Chinese Patients with HBeAg-Positive Disease Harboring Lamivudine-Resistant YMDD Mutations - (03/12/09)
     
  341. APASL: Use of the Elecsys® HBsAgII assay for simple and accurate quantification of HBsAglevels in sera of patients infected with HBV - (03/12/09)
     
  342. APASL: Evaluation of Long-term Entecavir (ETV) Treatment in Chronic Hepatitis B (CHB) Patients Switched from 24-week Lamivudine (LVD) Therapy - (03/11/09)
     
  343. CROI: The Long Term Use of Tenofovir Disoproxil in HIV-HBV Co-Infection Induces a Marked Decrease in Liver Fibrosis - (03/04/09)
     
  344. For the first time, doctors can predict which hepatitis B patients have the highest chance to achieve treatment success with Pegasys: new data reported at APASL, Asian Liver meeting - (02/27/09)
     
  345. CROI: HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection - (02/27/09)
     
  346. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: Phase II clinical study in Japan - (01/30/09)
     
  347. Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV - (01/22/09)
     
  348. EASL Clinical Practice Guidelines: Management of chronic hepatitis B - (01/20/09)
     
  349. NIH Consensus Development Conference: Management of Hepatitis B - (01/07/08)
     
  350. Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis - (01/05/08)
     
  351. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study - (12/30/08)
     
  352. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update - (12/23/08)
     
  353. AASLD: Pattern of serial HBV DNA level and HCC development in Patients with Liver Cirrhosis - (12/19/08)
     
  354. AASLD: On-Treatment HBsAgDecline During Peginterferon alfa-2a (40KD) ± Lamivudine in Patients With HBsAg-Positive CHB As A Potential Predictor Of Durable Off-Treatment Response - (12/05/08)
     
  355. AASLD: Efficacy And Safety Of Peginterferon Alfa-2a Versus Adefovir Dipivoxil (ADV) In Treating Lamivudine Resistant HBeAg-Positive CHB: An Interim Analysis Of A Prospective Randomized Study - (12/05/08)
     
  356. AASLD: Response Patterns Of Chinese Patients With Chronic Hepatitis B Who Achieved HBsAgClearance Through Treatment With Peginterferon Alfa-2a - (12/05/08)
     
  357. AASLD: A Multicenter, Open-Label Study Of Efficacy And Safety Of Peginterferon Alfa-2a (40KD) In Korean Patients With HBeAg-Positive CHB Harboring Lamivudine-Resistant YMDD Mutants - (12/05/08)
     
  358. ICAAC: Chronic Hepatitis B Virus (HBV) Infection in the HIV Outpatient Study (HOPS), 1996-2006: Prevalence in the Era of Evolving Interventions (12/02/08)
     
  359. AASLD: Correlation Between HBV cccDNA And HBsAgLevels And Their Reduction By Peginterferon Alfa-2a-Based Therapy In Patients With Chronic Hepatitis B - (12/01/08)
     
  360. AASLD: In Patients With HBeAg-Negative Chronic Hepatitis B, HBsAgSerum Levels Early During Treatment With Peginterferon Alfa-2a Predict HBsAgClearance up to 4 Years Post-Treatment - (12/01/08)
     
  361. AASLD: Kinetics Of HBsAgDecline During And Following Treatment of CHB: Early And Rapid HBsAgDecline During Peginterferon alfa-2a Is Predictive Of HBsAgClearance - (12/01/08)
     
  362. AASLD: Kinetics Of HBsAgDecline in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Peginterferon alfa-2a According to Genotype and its Association With Sustained HBsAgClearance 4 Years Post Treatment - (12/01/08)
     
  363. AASLD: Quantitative Assessment Of Serum HBsAgLevels Using The Elecsys HBsAgII Screening Assay: Results Of A Feasibility Study - (12/01/08)
     
  364. AASLD: New Data Suggest Long-Term Treatment with BARACLUDE (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B - (11/17/08)
     
  365. AASLD: Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD - (11/17/08)
     
  366. AASLD: PRESENCE OF rtA194T AT BASELINE DOES NOT REDUCE EFFICACY TO TENOFOVIR (TDF) IN PATIENTSWITH LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B - (11/17/08)
     
  367. AASLD: Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103 - (11/17/08)
     
  368. AASLD: Evaluation of Long-term Entecavir Treatment in Stable Chronic Hepatitis B Patients Switched from Lamivudine Therapy - (11/17/08)
     
  369. AASLD: Three Years of Entecavir (ETV) Re-treatment of HBeAg(-) ETV Patients Who Previously Discontinued Treatment: Results from Study ETV-901 - (11/17/08)
     
  370. AASLD: Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 103) - (11/06/08)
     
  371. AASLD: Histologic Assessment of Long-term Entecavir Treatmentin Chronic Hepatitis B Patients - (11/14/08)
     
  372. AASLD: Five Years of Continuous Entecavir for Nucleoside-naïve HBeAg(+) Chronic Hepatitis B: Results from Studies ETV-022/-901 - (11/14/08)
     
  373. AASLD: Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901 - (11/14/08)
     
  374. AASLD: Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/06/08)
     
  375. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? - (10/23/08)
     
  376. NIH Consensus Development Conference: Management of Hepatitis B - (10/23/08)
     
  377. New CDC Hepatitis B plan seeks to aid high-risk groups - (09/22/08)
     
  378. New CDC HBV Guidelines: focus on treatment/care/education instead of only screening/testing - (09/22/08)
     
  379. Risk factors for decreased bone density and effects of HIV on bone in the elderly - (09/03/08)
     
  380. U.S. Food and Drug Administration Approves Viread(R) [tenofovir] for Chronic Hepatitis B in Adults - (08/12/08)
     
  381. High-Dose HBV Vaccination Rechallenge - (07/16/08)
     
  382. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) - (07/09/08)
     
  383. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks - (07/01/08)
     
  384. EASL: SUSTAINED DURABILITY OF HBeAg SEROCONVERSION IN CHRONIC HEPATITIS B PATIENTS AFTER TREATMENT WITH TELBIVUDINE AND LAMIVUDINE - (05/28/08)
     
  385. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-β2b and ribavirin in patients with HBV/HCV co-infection - (05/27/08)
     
  386. EASL: An open-label, comparative, multicentre study of peginterferon alfa-2a (40KD) plus ribavirin in the treatment of patients chronically infected with HCV/HBV or HCV alone - (05/15/08)
     
  387. EASL: On-treatment HBsAgdecline in HBeAg-negative patients as a predictor of response to peginterferon alfa-2a (40KD) therapy 3 years off-treatment: potential for response-guided therapy - (05/15/08)
     
  388. EASL: HBV DNA suppression induced by peginterferon alfa-2a (40KD) but not by lamivudine results in HBsAgclearance and seroconversion at 3 years off-treatment - (05/15/08)
     
  389. EASL: Efficacy and safety of peginterferon alfa-2a (40KD) in Chinese patients with HBeAg-positive chronic hepatitis B - (05/15/08)
     
  390. EASL: Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with PEGASYS with or without lamivudine: results of 4-year follow-up: 11% HBsAgClearance - (05/02/08)
     
  391. EASL: Entecavir (ETV) Results in Higher HBV DNA Reduction versus Adefovir (ADV) in Antiviral-naive HBeAg(+) Adults with High HBV DNA: Week 96 Results (E.A.R.L.Y. Study) - (05/01/08)
     
  392. EASL: Important Progress Toward Control of Hepatitis B and C - (05/01/08)
     
  393. EASL: Increasing HBV Viral Load Increases Risk for Liver Cancer--Serial Monitoring of Viral load and Serum Alanine Aminotransferase (ALT) Level and the Risk of Hepatocellular Carcinoma: R.E.V.E.A.L- HBV Study Update - (04/30/08)
     
  394. EASL: Three Years of Continuous Treatment with Entecavir Results in High Proportions of Chinese Nucleoside-Naive Patients with Undetectable HBV DNA: Results from Studies ETV-023 and -050 - (04/30/08)
     
  395. EASL: Three Years of Continuous Treatment in Chinese Patients who had Previously Failed Lamivudine: Results from Studies ETV-056 and ETV-050 - (04/30/08)
     
  396. EASL: Long Term (3 Years) Efficacy, Safety and Resistance Analyses of Entecavir (ETV) Treatment in Japanese Nucleoside-naive Patients with Chronic Hepatitis B (CHB) - (04/30/08)
     
  397. EASL: Increasing Serial HBV Viral Load & ALT Predicts HCC - (04/29/08)
     
  398. EASL: BARACLUDE (ENTECAVIR) TREATMENT RESULTED IN GREATER VIRAL LOAD SUPPRESSION COMPARED TO ADEFOVIR AT 96 WEEKS IN ANTIVIRAL-NAIVE ADULT CHRONIC HEPATITIS B E-ANTIGEN POSITIVE PATIENTS - (04/29/08) BMS press release
     
  399. EASL: Hepatitis B an issue 'too hot to handle' in Australia - (04/29/08)
     
  400. EASL: A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV MONO-INFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOGUE EXPERIENCE - (04/29/08)
     
  401. EASL: The Antiviral Response To Tenofovir Disoproxil Fumarate (TDF) is Comparable in Lamivudine (LAM)-NaIve and LAM-Experienced Subjects Treated for Chronic Hepatitis B (CHB) - (04/29/08)
     
  402. EASL: Tenofovir Disoproxil Fumarate (TDF) is Highly Active for Treatment of Chronic Hepatitis B (CHB) in Patients With Cirrhosis - (04/29/08)
     
  403. EASL: Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) - (04/29/08)
     
  404. EASL: Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Positive Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 103) - (04/29/08)
     
  405. EASL: Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - (04/29/08)
     
  406. EASL: Liver Disease Progression in Chronic Hepatitis B Infected Persons With Persistently Normal Serum Alanine Aminotransferase Level: Update From the R.E.V.E.A.L.-HBV Study - (04/29/08)
     
  407. EASL: Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - (04/29/08)
     
  408. EASL: European Commission Approves Viread(R) for Chronic Hepatitis B - (04/25/08)
     
  409. EASL: GILEAD ANNOUNCES 72-WEEK DATA FROM TWO PIVOTAL PHASE III STUDIES EVALUATING VIREAD (tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (04/24/08)
     
  410. Chronic Hepatitis B: Preventing, Detecting, and Managing Viral Resistance - (04/21/08)
     
  411. Entecavir Therapy Induces de Novo HIV Reverse-Transcriptase M184V Mutation in an Antiretroviral Therapy-Naive Patient BRIEF REPORT - (04/04/08)
     
  412. APASL: Entecavir at Five Years Shows Long Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance - (03/25/08)
     
  413. APASL: BARACLUDE (ENTECAVIR) DATA CONTINUE TO DEMONSTRATE LOW INCIDENCE OF RESISTANCE THROUGH FIVE YEARS OF TREATMENT IN NUCLEOSIDE-NAIVE CHRONIC HEPATITIS B PATIENTS (BMS press announcement) - (03/25/08)
     
  414. APASL: Efficacy and Safety of 3 Years Treatment with Entecavir (ETV) in Japanese Nucleoside-Naive Patients with Chronic Hepatitis B (CHB) - (03/25/08)
     
  415. APASL: Three Years of Continuous Treatment in Chinese Patients who had Previously Failed Lamivudine: Results from Studies ETV-056 and ETV-050 - (03/25/08)
     
  416. EUROPEAN CHMP ISSUES POSITIVE OPINION FOR VIREAD (tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (03/20/08)
     
  417. HIV and hepatitis B co-infection in Africa Reflection and Reaction - (03/20/08)
     
  418. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa Review - (03/20/08)
     
  419. CROI: Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals - (03/19/08)
     
  420. Occult hepatitis B virus in liver tissue of individuals without hepatic disease - (03/14/08)
     
  421. Combination therapy for chronic hepatitis B: Ready for prime time? Editorial - Written by Ira M. Jacobson - (03/10/08)
     
  422. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations - (03/05/08)
     
  423. Potency of tenofovir in chronic hepatitis B: Mono or combination therapy? Editorial - (03/05/08)
     
  424. Goal of HBV Therapy - Prevent Resistance - (01/07/08)
     
  425. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  426. Thousands of Canadians may be denied access to effective new hepatitis B treatment: Drug review committee recommends against full reimbursement of Baraclude (TM) (entecavir) - (12/05/07)
     
  427. Hepatitis B Clinical Research Network Starts - (12/04/07)
     
  428. The clinical significance of persistently normal ALT in chronic hepatitis B infection - (12/04/07)
     
  429. Frequent Occurrence of Chronic Hepatitis B Virus Infection among West African HIV Type-1-Infected Children - (01/03/08)
     
  430. Hepatitis B Virus and HIV Coinfection in Low-Income Countries: Unmet Needs EDITORIAL COMMENTARY - (01/03/08)
     
  431. Tenofovir-Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine BRIEF REPORT - (01/03/08)
     
  432. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  433. Thousands of Canadians may be denied access to effective new hepatitis B treatment: Drug review committee recommends against full reimbursement of Baraclude(TM) (entecavir) - (12/05/07)
     
  434. Hepatitis B Clinical Research Network Starts - (12/04/07)
     
  435. The clinical significance of persistently normal ALT in chronic hepatitis B infection - (12/04/07)
     
  436. New wave of immigration blamed for doubling of hepatitis B cases in UK - (11/28/07)
     
  437. Most UK citizens susceptible to hep B infection - (11/28/07)
     
  438. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus - (11/27/07)
     
  439. AASLD: Decline in the Need for Liver Transplantation for Endstage Liver Disease Secondary to Hepatitis B in the US - (11/26/07)
     
  440. Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B - (11/19/07)
     
  441. Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients - (11/19/07)
     
  442. Hepatitis B: Explosion of New Knowledge; Comments by E Keefe - (11/19/07)
     
  443. AASLD: Reduction in serum HBsAglevel in patients with chronic hepatitis B infected with genotype D induced by (pegylated) interferon alfa-2a alone or in combination with nucleos(t)ide analogs: a long-term single centre cohort study - (11/16/07)
     
  444. AASLD: Long-term follow-up of HBsAgclearance in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (PEGASYS): increase in HBsAgclearance rate from 3% 6 months post-treatment to 8% after 3 years - (11/16/07)
     
  445. AASLD: An Open Label, Comparative, Multicenter Study Of Peginterferon Alfa-2a Plus Ribavirin In The Treatment Of Patients With Chronic Hepatitis C/Hepatitis B Dual Infection Versus Those With Chronic Hepatitis C Mono-infection - (11/16/07)
     
  446. AASLD: Real-Time PCR Quantification of Total Intracellular HBV DNA and cccDNA in HBsAg-Positive Patients with and without HDV co-Infection and in Patients with Occult HBV Infection - (11/16/07)
     
  447. AASLD: First Multicenter Evaluation of the Efficacy of Tenofovir in Nucleo(t)ide Analog Experienced Patients with HBV Monoinfection - (11/14/07)
     
  448. AASLD: Efficacy of Tenofovir DF for the Treatment of Adefovir Resistance - (11/14/07)
     
  449. AASLD: Fatty Liver Associated with Metabolics in HBV+ - (11/14/07)
     
  450. AASLD: Large Scale Longitudinal Study of Chronic Hepatitis B Patients with Hepatitis B Surface Antigen Seroclearance - (11/7/07)
     
  451. AASLD: A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103 - (11/7/07)
     
  452. AASLD: A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg-Negative Chronic Hepatitis B (CHB): Study GS-US-174-0102 - (11/7/07)
     
  453. AASLD: HBV Viral Load Less Than 10,000 copies/mL Is Associated with Significant Risk of Hepatocellular Carcinoma in Chronic Hepatitis B (CHB) Patients: An Update from the R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  454. AASLD: Impact of chronically elevated HBV DNA viral load on risk of HCC occurrence: An update from The R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  455. AASLD: Changes in Serum HBV DNA Level Using a Trajectory Model to Predict the Risk of HCC in Chronic Hepatitis B Patients: The R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  456. AASLD: Gilead's Tenofovir beats Hepsera in second big HBV trial - (11/7/07)
     
  457. AASLD: Four-Year Entecavir Treatment in Nucleoside-Naive, HBeAg(+) Patients: Results from Studies ETV-022 and -901 - (11/5/07)
     
  458. AASLD: Long-Term Follow-Up of Entecavir Treated Protocol-Defined 'Non-Responders' in Rollover Study ETV-901 - (11/5/07)
     
  459. Why we should routinely screen Asian American adults for hepatitis B: A cross-sectional study of Asians in California - (10/17/07)
     
  460. GILEAD SUBMITS MARKETING APPLICATIONS IN THE UNITED STATES AND EUROPEAN UNION FOR VIREAD (TENOFOVIR DISOPROXIL FUMARATE) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (10/12/07)
     
  461. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV - (10/02/07)
     
  462. Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B - (08/20/07)
     
  463. Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women - (08/17/07)
     
  464. Novartis/Idenix Launch Free Telbivudine HBV Drug Program for HBV Therapy - (08/14/07)
     
  465. Screening for and Treating Hepatitis B Virus in Patients with HIV Infection EDITORIAL - (08/10/07)
     
  466. Impact of HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion - (08/10/07)
     
  467. Hepatitis B Virus and HIV Coinfection: Results of a Survey on Treatment Practices and Recommendations for Therapy - (08/10/07)
     
  468. Incidence (3 times higher) of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection - (07/16/07)
     
  469. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis - (07/16/07)
     
  470. The HBV Asian Epidemic You Don't Know About - (07/06/07)
     
  471. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection - (07/05/07)
     
  472. The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points (HBV-DNA, ALT) - (07/03/07)
     
  473. SECOND PHASE III STUDY EVALUATING GILEAD'S VIREAD (Tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS MEETS PRIMARY ENDPOINT - (06/27/07)
     
  474. Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint - (06/07/07)
     
  475. DDW: Patient survey, Many hepatitis B patients stop taking meds - (05/31/07)
     
  476. Predicting response to peginterferon a-2a (Pegasys), lamivudine and the two combined for HBeAg-negative chronic hepatitis B; genotype may predict response to combination therapy - (05/25/07)
     
  477. DDW: A Randomized Trial of Telbivudine vs Adefovir for HBeAg-Positive Chronic Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of Switching to Telbivudine - (05/25/07)
     
  478. DDW: A Phase III Comparative Trial of Telbivudine vs Lamivudine in Chinese Patients With Chronic Hepatitis B: Two-Year Results - (05/25/07)
     
  479. DDW: Causes of Death Associated With Hepatitis B or Hepatitis C Virus Infections in a Long-Term Population-Based Cohort Study - (05/24/07)
     
  480. DDW: Salvage Therapy With Adefovir for Virologic Breakthrough in Telbivudine-Treated Patients From the GLOBE Study - (05/23/07)
     
  481. DDW: Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common Even When ALT is Less Than 2 x ULN in Patients with Chronic Hepatitis B (CHB) in Entecavir Studies ETV-022 (HBeAg+) and ETV-027 (HBeAg-) - (05/23/07)
     
  482. DDW: Genotypic Analysis of Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the GLOBE Registration Trial - (05/23/07)
     
  483. DDW: Resistance Determination in Patients Experiencing Virologic Breakthrough Following Telbivudine or Lamivudine Therapy in the International GLOBE Trial - (05/23/07)
     
  484. DDW: BARACLUDE (ENTECAVIR) TREATMENT DEMONSTRATED GREATER VIRAL LOAD REDUCTION COMPARED TO ADEFOVIR AT 48 WEEKS IN STUDY OF ANTIVIRAL-NAIVE CHRONIC HEPATITIS B E-ANTIGEN POSITIVE PATIENTS - (05/23/07)
     
  485. DDW: Telbivudine GLOBE Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B - (05/21/07)
     
  486. DDW: HBV DNA & Genotype Predict HCC - (05/21/07)
     
  487. DDW: HBV DNA & ALT Predict HCC in HBV+ - (05/21/07)
     
  488. HBV Exposure May Increase HCC Risk Among HCV+ with Cirrhosis, Japan study reports - (05/04/07)
     
  489. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B - (05/04/07)
     
  490. Novartis gets European OK for hepatitis B drug Sebivo (telbivudine) - (05/01/07)
     
  491. EASL: An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07)
     
  492. EASL: EFFECTS OF INSULIN SENSITIZING AGENTS IN NONALCOHOLIC FATTY LIVER DISEASE, METABOLICS: metformin, rosiglitazone, metformin+rosiglitazone - (04/23/07)
     
  493. EASL: 76 Week Follow-up of HBeAg-Positive Chronic Hepatitis B Patients Treated with Telbivudine, Adefovir or Switched from Adefovir to Telbivudine - (04/23/07)
     
  494. EASL: HBV rtI233V Polymerase Variant Remains Sensitive to Adefovir - (04/23/07)
     
  495. EASL: Pegasys Superior to Lamivudine Over 3 Years in HBV DNA Decline, ALT Normalization & HBsAgLoss (8% vs 0) & Seroconversion (4% vs 0) - (04/23/07)
     
  496. EASL: Peginterferon a-2a Plus adefovir vs Peginterferon a-2a for 48 Weeks in HBeAg-Negative Chronic Hepatitis B: Preliminary 24-Week Results of the PEG FOR B Randomized Multicenter Trial - (04/23/07)
     
  497. EASL: Efficacy of Entecavir and Lamivudine in Chronic Hepatitis B Patients with Advanced Liver Fibrosis/Cirrhosis - (04/19/07)
     
  498. EASL: Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common even when ALT is less than 2 X ULN in Patients with Chronic Hepatitis B - (04/19/07)
     
  499. EASL: Entecavir (ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) in Chronically Infected HBeAg(+) Antiviral-Naive Adults: 48-Wk Results (E.A.R.L.Y. Study) - (04/17/07)
     
  500. EASL: Four Year Assessment Of Entecavir Resistance In Nucleoside Naive and Lamivudine Refractory Patients - (04/17/07)
     
  501. EASL: Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients (press release from BMS) - (04/17/07)
     
  502. EASL: BARACLUDE (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment (press release from BMS) - (04/17/07)
     
  503. EASL: ETV Re-treatment of Nucleoside-Naive HBeAg(-) Patients with Recurrent Viremia - (04/17/07)
     
  504. China Approves Schering-Plough's Pegintron for Hepatitis B - (04/05/07)
     
  505. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/05/07)
     
  506. CROI: Hepatitis B Virus (HBV) Dynamics in HIV-HBV Co-infected Patients: Significant Difference in the Viral Activity of Adefovir (ADV) or Tenofovir (TDF) (03/09/07)
     
  507. SEBIVO(R) (telbivudine) Recommended for Approval in European Union as a new Treatment for Patients with Chronic Hepatitis B - (02/27/07)
     
  508. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B - (02/12/07)
     
  509. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years - (01/30/06)
     
  510. New and Emerging Treatment of Chronic Hepatitis B - (01/30/06)
     
  511. Hepatitis B Virus Treatment in HIV-infected Patients - (01/30/06)
     
  512. Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator Peginterferon on Treatment of Chronic Hepatitis B - (12/17/06)
     
  513. Combination Therapy for Chronic Hepatitis B: Simultaneous or Sequential? EDITORIAL - (12/17/06)
     
  514. Idenix announces telbivudine for chronic hepatitis B patients approved in Switzerland - (12/07/06)
     
  515. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient - (12/07/06)
     
  516. Hepatitis B virus resistance to entecavir in nucleoside naive patients: Does it exist Editorial - (12/07/06)
     
  517. Entecavir resistance is rare in nucleoside naive patients with hepatitis B - (12/07/06)
     
  518. AASLD: No Novel Adefovir Mutations - (11/08/06)
     
  519. AASLD: Pegasys/RBV Prophylaxisly Administered After Liver Transplant - (11/08/06)
     
  520. AASLD: RBV Exposure During weeks 1-12 of Treatment Improves SVR Rate in Canadian Pegasys EAP - (11/08/06)
     
  521. AASLD: Pegasys + Adefovir Reduces HBsAgin HDV-Coinfected - (11/07/06)
     
  522. AASLD: Pegasys+Lamivudine for HBeAg-negative, 2 Year Follow-up - (11/07/06)
     
  523. AASLD: Anti-HBV Activity of In Vitro Combinations of Tenofovir with Nucleoside Analogs - (11/06/06)
     
  524. AASLD: In Vitro Susceptibility of HBV Polymerase Encoding Mutations Acquired During Adefovir Dipivoxil Therapy to Other Anti-HBV Agents - (11/06/06)
     
  525. AASLD: Entecavir Resistance 3-Year Update at AASLD - (11/02/06)
     
  526. AASLD: Entecavir 3-Year Resistance Update - (11/02/06)
     
  527. AASLD: Entecavir 3-Year Efficacy/Safety Update in HBeAg+ Naives - (11/02/06)
     
  528. AASLD: Entecavir 3-Year Update on Efficacy & Safety - (11/02/06)
     
  529. AASLD: Two-Year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine - (11/01/06)
     
  530. ICAAC: Can Razor Blades Transmit Hepatitis B? - (10/02/06)
     
  531. World Hepatitis Awareness Day October 1, 2006 - (10/02/06)
     
  532. BMS Announces Baraclude (entecavir) Now Available In The UK For Treatment Of Chronic Hepatitis B - (09/21/06)
     
  533. Novartis wins first major nod for hep B drug - (09/21/06)
     
  534. Antiretroviral Therapy for Hepatitis B Virus-HIV-Coinfected Patients: Promises and Pitfalls - (09/18/06)
     
  535. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-α2b plus ribavirin treatment in a patient with hepatitis B and C coinfection - (09/15/06)
     
  536. Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis - (09/11/06)
     
  537. Liver transplants can be successful in HIV patients with hepatitis B - (09/07/06)
     
  538. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response - (09/05/06)
     
  539. Past HBV Viral Load as Predictor of Mortality and Morbidity from HCC and Chronic Liver Disease in a Prospective Study - (08/01/06)
     
  540. Tenofovir disoproxil fumarate: Role in hepatitis B treatment - (08/01/06)
     
  541. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy - (08/01/06)
     
  542. Tenofovir disoproxil fumarate: Role in hepatitis B treatment - (08/01/06)
     
  543. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy - (08/01/06)
     
  544. Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B - (07/30/06)
     
  545. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update - (07/27/06)
     
  546. FDA committee favors Nabi hepatitis B drug for Post-Transplant - (07/14/06)
     
  547. Hepatitis B Vaccination Coverage Among Adults --- United States, 2004 - (07/07/06)
     
  548. European Commission Grants Approval for BARACLUDE(R) (entecavir) for Treatment of Chronic Hepatitis B - (06/29/06)
     
  549. DDW: Safety and Efficacy of Adefovir Dipivoxil in Patients with Lamivudine-Resistant Chronic HBV Undergoing Liver Transplantation - (05/26/06)
     
  550. DDW: A COMPARATIVE TRIAL OF TELBIVUDINE AND ADEFOVIR DIPIVOXIL FOR TREATMENT OF HBeAg-POSITIVE, COMPENSATED CHRONIC HEPATITIS B: 24 WEEK RESULTS - (05/26/06)
     
  551. DDW: Predictive Factors for Exacerbation of Hepatitis B After Discontinuation of Oral Therapy in HBeAg-Negative Patients - (05/26/06)
     
  552. DDW: Entecavir 96 Weeks in Lamivudine-Refractory HBeAg(+): efficacy, safety, resistance - (05/26/06)
     
  553. 15% HBV Prevalence in NYC Among Asians - (05/16/06)
     
  554. EASL: HBV Resistance Determination From the Telbivudine GLOBE Registration Trial - (05/16/06)
     
  555. EASL: Pharmacokinetics and Pharmacodynamics of Pradefovir Mesylate, a Liver-Targeting Pro-Drug of PMEA, in HBV Patients - (05/16/06)
     
  556. EASL: Clevudine 48 Weeks - (05/16/06)
     
  557. EASL: Safety, Tolerability and Antiviral Activity of Pradefovir Mesylate in Patients with Chronic Hepatitis B Virus Infection: 48-Week Analysis of a Phase 2 Study - (05/16/06)
     
  558. EASL: Telbivudine, New HBV Drug: Early Viral Response Predicts Outcomes - (05/10/06)
     
  559. EASL: A Randomized Trial of Telbivudine (LdT) vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis - (05/10/06)
     
  560. EASL: Association Between HBeAg Seroconversion and Sustained HBV DNA Suppression in Patients Treated with Peginterferon Alfa-2a (40 KD) (Pegasys) for HBeAg-positive Chronic Hepatitis B - (05/08/06)
     
  561. EASL: Durability of HBeAg Seroconversion Following Adefovir Dipivoxil Treatment for Chronic Hepatitis B - (05/08/06)
     
  562. Association Between HBeAg Seroconversion and Sustained HBV DNA Suppression in Patients Treated with Peginterferon Alfa-2a (40 KD) (Pegasys) for HBeAg-positive Chronic Hepatitis B - (05/05/06)
     
  563. EASL: Combination HBV Therapy (lamivudine+adefovir) Prevented HBV-DNA Viral Rebound and Adefovir Resistance Compared to Adefovir Monotherapy in Cirrhotics - (05/04/06)
     
  564. EASL: Entecavir Improved Fibrosis in Advanced Liver Disease More Than Lamivudine in 3 Pivotol Studies After 48 Weeks Therapy - (05/04/06)
     
  565. EASL: Entecavir vs Lamivudine in 515 Treatment-Naives: safety & efficacy - (05/04/06)
     
  566. Outcome of patients with hepatitis B virus and HIV referred for liver transplantation - (05/03/06)
     
  567. HBV/HIV Coinfection: Timing in Treatment & Referral for Transplantation and Suppression HBV Replication Are Crucial - (05/03/06)
     
  568. EASL: Adefovir 5 years Viral & Resistance Outcomes in HBeAg-negatives - (05/03/06)
     
  569. EASL: High Barrier To Resistance Results In No Emergence Of Entecavir Resistance In Nucleoside Naive Subjects During The First Two Years Of Therapy - (05/02/06)
     
  570. EASL: Entecavir 96 weeks in HBeAg(-), study ETV-027 - (04/19/06)
     
  571. Entecavir (ETV) vs. Adefovir (ADV): HBV DNA Reduction In Chronically Infected HBeAg(+) Nucleoside-Naive Adults In A 12-Week Viral Kinetics Study - (04/07/06)
     
  572. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome - (04/05/06)
     
  573. Idenix Files in china for Telbivudine Approval, new HBV Drug - (04/05/06)
     
  574. Idenix Announces 13 Abstracts on Hepatitis B and C Accepted for the 2006 Annual Meeting of the European Association for the Study of the Liver (EASL) - (04/05/06)
     
  575. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection - (04/05/06)
     
  576. Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers - (04/05/06)
     
  577. Novartis files telbivudine in China for Hep B - (03/29/06)
     
  578. Personal view: the management of chronic hepatitis B infection - (03/21/06)
     
  579. HBV Drug Pradefovir Phase 2 48 Week Study Results - (03/15/06)
     
  580. Management of Recurrent Viral Hepatitis B and C After Liver Transplantation - (03/15/06)
     
  581. HBV DNA Early Response Predicts IFN Nonresponse - (03/15/06)
     
  582. Entecavir, Hepatitis B Drug Phase III Study Results in HBsAg - (03/09/06)
     
  583. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B - (03/09/06)
     
  584. Hepatitis Delta Virus Levels May Predict Disease Severity in HBV - (03/09/06)
     
  585. CROI: Tenofovir + Lamivudine (3TC) for HBV/HIV Coinfection (03/07/06)
     
  586. Tenofovir in HBV/HIV Coinfection, added to Lamivudine - (03/03/06)
     
  587. Combination therapy for chronic hepatitis B: A one-two knockout punch, or a swing and a miss? - (03/03/06)
     
  588. CROI: Hepatitis D Virus Can Worsen the Outcome of HBV-HIV Coinfected Patients (02/23/06)
     
  589. Gilead Sciences Launches Stop Hep B Campaign - (02/10/06)
     
  590. Idenix/Novartis Apply for Telbivudine European OK - (02/08/06)
     
  591. Treatment with Peg-Interferon a-2b for HBeAg-Positive Chronic Hepatitis B: HBsAgLoss Is Associated with HBV Genotype - (02/08/06)
     
  592. Therapeutic Options for Chronic Hepatitis B: Considerations and Controversies, part 1 - (02/02/06)
     
  593. Looking to the Future: New Agents for Chronic Hepatitis B, part 2 - (02/02/06)
     
  594. Advancing Patient Care: Integrating New Data, part 3 - (02/02/06)
     
  595. Selecting Appropriate Management Strategies for Chronic Hepatitis B: Who to Treat, part 4 - (02/02/06)
     
  596. Optimizing Management Strategies in Special Patient Populations, part 5 - (02/02/06)
     
  597. Introduction to Chronic Hepatitis B Infection, last part 6 of 6 - (02/02/06)
     
  598. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV: HBV genotype G found to be associated with liver fibrosis - (01/31/06)
     
  599. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons - (01/31/06)
     
  600. HBV+HCV+HDV-dynamic diseases when in combination - (01/30/06)
     
  601. Vaccination of Infants of Hepatitis B Mothers - (01/30/06)
     
  602. Virologic response and resistance to adefovir in patients with chronic hepatitis B, & Entecavir Salvage Therapy - (01/25/06)
     
  603. Candidates for therapy: HBV - (01/24/06)
     
  604. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management - (01/24/06)
     
  605. Natural history of chronic hepatitis B in co-infected patients - (01/24/06)
     
  606. "Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?" - (01/23/06)
     
  607. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication - (01/23/06)
     
  608. Management of hepatocellular carcinoma in HIV- infected patients - (01/23/06)
     
  609. Intl Coinfection Wrkshp: HBV Drug Resistance & Cross-Resistance (01/20/06)
     
  610. Intl Coinfection Wrkshp: New Drugs for HCV & HBV (01/17/06)
     
  611. New Drug HepeX-B To Prevent HBV Post-Transplant Reinfection - (01/04/06)
     
  612. Telbivudine Continues to Show Superior Efficacy over Lamivudine in Chronic HBV in Continuing GLOBE trial, 18 Mos: Presented at HEP DART - (01/04/06)
     
  613. Adefovir Dipivoxil Produces sustained improvement in HBV over Long-Term; Presented at HEP DART - (01/04/06)
     
  614. New HBV Drug Telbivudine: NDA submitted to FDA - (01/04/06)
     
  615. HBV DNA (viral load) Predicts Risk for Liver Cancer - (01/04/06)
     
  616. EACS: HAART & SVR in APRICOT Study (12/29/05)
     
  617. Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Efficacy In Phase 2/3 Clinical Trial - (12/21/05)
     
  618. Impact of tenofovir-containing ART on chronic HBV in a cohort co-infected with HIV - (12/12/05)
     
  619. Treat HBV Immediately Upon Detecting Genotypic Resistance - (12/08/05)
     
  620. AASLD: Pradefovir, New HBV Drug: 24 Wks (12/05/05)
     
  621. AASLD: 5 Years Adefovir in HBeAg-Negatives (12/05/05)
     
  622. AASLD: Clevudine, new HBV Drug: 24 week study results (12/05/05)
     
  623. AASLD: Long-term effect of tenofovir in the treatment of lamivudine-resistant HBV in comparison to adefovir (12/02/05)
     
  624. AASLD: Normal ALT & Low HBV-DNA May Be Risk for Cirrhosis & HCC (11/28/05)
     
  625. AASLD: Serum Leptin Level Associated with Severity of Liver Fibrosis & Decreased After Pegasys Treatment in Chronic Hepatitis B (11/28/05)
     
  626. AASLD: Low Rate of Viral Rebound Seen in HBV Patients Treated With Entecavir (11/28/05)
     
  627. AASLD: Entecavir 2 Years Study Results in HBeAg+ HBV+ Patients (study ETV-22) (11/16/05)
     
  628. AASLD: Five-Year Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting (11/15/05)
     
  629. AASLD: BARACLUDE (entecavir) TWO-YEAR DATA ANALYSIS DID NOT DETECT EMERGENCE OF RESISTANCE IN NUCLEOSIDE-NAIVE CHRONIC HEPATITIS B PATIENTS (11/14/05)
     
  630. AASLD: SEVERE IMPAIRMENT IN QUALITY OF LIFE IN HIV+ WITH HCV BUT NOT WITH HBV (11/14/05)
     
  631. AASLD: HEPATITIS B: SCIENCE & TREATMENT 2005 (11/11/05)
     
  632. New Liver Cancer Therapy Approach Improves Survival - (11/07/05)
     
  633. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women - (11/07/05)
     
  634. INTERFERON THERAPY FOR CHRONIC HEPATITIS B and Combination Interferon + Lamivudine - (11/07/05)
     
  635. HCC (Liver Cancer) Deaths Doubled & Hospital Services Costs Increase Significantly - (11/05/05)
     
  636. Entecavir RESISTANCE - (11/03/05)
     
  637. Hepatitis B Survey Among Asians Highlights Lack of Information About HBV - (11/03/05)
     
  638. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity - (11/03/05)
     
  639. Entecavir Treatment for HBV in Woodchucks - (10/27/05)
     
  640. Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project) - (10/27/05)
     
  641. Epidemiology, Natural History, Impact of Therapy of Hepatitis B - (10/24/05)
     
  642. Hepatits B Treatment - (10/24/05)
     
  643. "Predicting survival in hepatitis B" Should Targeted HBV DNA Suppression Be the Goal of Therapy? - (10/21/05)
     
  644. Hep B Booster Shot Unnecessary: Study - (10/21/05)
     
  645. Hepatitis B and Liver Transplantation - (10/21/05)
     
  646. The impact of maternal HBsAgcarrier status on pregnancy outcomes: A case-control study - (10/14/05)
     
  647. Hepatitis B in India: 3% HBsAg+ - (10/13/05)
     
  648. Long-Term Interferon+Lamivudine for HBV in HBeAg-Negatives - (10/13/05)
     
  649. Hepatitis B Vaccine: is it associated with Autism? - (10/11/05)
     
  650. Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B - (10/11/05)
     
  651. Adefovir Resistance: clinical outcomes - (10/11/05)
     
  652. Asian Americans & Hepatitis B - (10/06/05)
     
  653. New HCV Drug NM283 HBV Drug LdT at AASLD - (10/03/05)
     
  654. New HBV Therapy Research for siRNAs - (10/03/05)
     
  655. Hepatitis B in children: Complexities in management - (10/03/05)
     
  656. NIH Hepatitis B Management Conference: 2006 - (09/28/05)
     
  657. Broadeining Hepatitis B Vaccination considered for all adults - (09/21/05)
     
  658. Hepatitis B and HIV co-infection in sub-Saharan Africa: a call for further investigation - (09/21/05)
     
  659. 6.3% Prevalence of hepatitis B and C in pregnant women who are infected with HIV - (09/21/05)
     
  660. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics - (09/20/05)
     
  661. Covalently Closed Circular DNA Is the Predominant Form of Duck Hepatitis B Virus DNA That Persists following Transient Infection.....inactive/nonreplicating cccDNA - (09/20/05)
     
  662. Peginterferon for HBV Therapy: review of studies - (09/19/05)
     
  663. September is Liver Cancer Awareness Month - (09/19/05)
     
  664. (Marijuana/Hash) Endocannabinoids and liver disease - review - (09/19/05)
     
  665. Stressgen Granted U.S. Patent Covering Therapeutic Products to Treat Hepatitis B Virus - (09/06/05)
     
  666. HBV, pathogenesis and natural course - (09/06/05)
     
  667. Promising Therapy for Human Hepatoma (liver cancer, HCC): Telomerase Inhibition by GRN163 - (09/13/05)
     
  668. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain - (09/13/05)
     
  669. Pegasys for HBV: what is the treatment role? - (09/06/05)
     
  670. HBV Genotype May Predict Cirrhosis - (09/06/05)
     
  671. Does HBV Genotype Predict Response to IFN - (09/06/05)
     
  672. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy - (08/15/05)
     
  673. Telbivudine (LdT) Achieves Primary Endpoint in Phase III GLOBE Trial, Largest Ever Registration Trial in HBV - (08/04/05)
     
  674. Gilead Announces Initiation of Phase III Study of Tenofovir for the Treatment of Chronic Hepatitis B Virus - (07/22/05)
     
  675. New Hep B Drug Pradefovir: 24 week data - (07/22/05)
     
  676. Peginterferon more effective than lamivudine for chronic hepatitis B - (07/05/05)
     
  677. Long-Term Therapy Required for HBeAg-Negative Patients: Adefovir HBV Therapy in HBeAg-negative Patients Maintains Benefits on Therapy for 144 Weeks; Upon Discontinuation of Therapy Rebound Occurs - (06/30/05)
     
  678. The Maze of Treatments for Hepatitis B - (06/30/05)
     
  679. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B - (06/30/05)
     
  680. Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B - (06/30/05)
     
  681. Pharmasset to Develop Clevudine for the Treatment of Chronic Hepatitis B under a License from Bukwang Pharmaceuticals - (06/28/05)
     
  682. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study - (06/27/05)
     
  683. DDW: Resistance to Adefovir (Hepsera) Can Be Associated with Significant Virologic Breakthough and Fatal Hepatic Decompensation (06/20/05)
     
  684. HBV & Risk for Cancers Outside the Liver - (06/01/05)
     
  685. New HCV & HBV Drugs: toll-like receptors - (06/01/05)
     
  686. New Perspectives in the Treatment of HBeAg-positive and HBeAg-negative Chronic Hepatitis B pegylated interferon - (05/31/05)
     
  687. Hepatitis virus-positive livers OK for transplants - (05/27/05)
     
  688. HBV Drug LdT: 2 years followup: Phase IIb Extended-Treatment Trial of Telbivudine (LdT) vs. Lamivudine vs. Combination Treatment in Hepatitis B Patients: Two-Year Results - (05/26/05)
     
  689. New Perspectives in the Treatment of HBeAg-positive and HBeAg-negative Chronic Hepatitis B - (05/25/05)
     
  690. Hepatitis virus-positive livers OK for transplants - (05/27/05)
     
  691. HBV Drug LdT: 2 years followup: Phase IIb Extended-Treatment Trial of Telbivudine (LdT) vs. Lamivudine vs. Combination Treatment in Hepatitis B Patients: Two-Year Results - (05/26/05)
     
  692. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate - (05/25/05)
     
  693. DDW: HBV DNA Elevations & Risk for Liver Cancer (05/23/05)
     
  694. DDW: HBV Viral Load Predicts Cirrhosis Risk (05/19/05)
     
  695. DDW: "Viral Load is a Strong Predictor of Hepatocellular Carcinoma (HCC) Risk in People Chronically Infected With Hepatitis B Virus (HBV) Independent of Serum Alanine Aminotransaminase Level (ALT)" (05/19/05)
     
  696. DDW: Entecavir 24 Week Followup Off-Treatment in HBeAg+ (05/19/05)
     
  697. DDW: HEPATITIS B: SCIENCE & TREATMENT 2005 (05/16/05)
     
  698. DDW: Pioglitazone Improves Fatty Liver (05/16/05)
     
  699. FDA Approves Pegasys(R) as the First and Only Pegylated Interferon for the Treatment of Chronic Hepatitis B - (05/16/05)
     
  700. Can HBV Replicate Extrahepatically? - (05/16/05)
     
  701. HIV-infected patients with isolated anti-HBc antigen may require HBV vaccine - (05/13/05)
     
  702. Tenofovir Dosing in HBV - (05/09/05)
     
  703. Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection - (05/09/05)
     
  704. Is HBV Curable: effect of lamivudine (3TC) on cccDNA - (05/09/05)
     
  705. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B - (05/09/05)
     
  706. Hepatitis B Immunity in United States Military Recruits - (05/09/05)
     
  707. May 13 is Hepatitis B Awareness Day - (05/09/05)
     
  708. EASL: Lack of Pharmacokinetic Interaction When Entecavir is Co-Administerd with Lamivudine,, Adefovir, or Tenofovir and Entecavir Dosing with Renal Impairment (05/05/05)
     
  709. EASL: HBV DNA (viral load) Predicts Liver Cirrhosis (05/02/05)
     
  710. EASL: Tenofovir in HIV/HBV Coinfection (05/02/05)
     
  711. EASL: Effect of Previous HBV Therapy on Pegasys+Lamivudine for HBV (05/02/05)
     
  712. EASL: HBV Viral Load Risk Factor for Liver Cancer (04/27/05)
     
  713. EASL: Diabetes & Lipids Associated with Liver Disease (04/27/05)
     
  714. EASL: Adefovir for HBV HBeAg-negative: 4 years- safety, antiviral efficacy, resistance, ALT normalization, creatinine & phosphorous (04/27/05)
     
  715. EASL: HBV DNA Decline & ALT Normalization Associated with Histologic Improvement (04/27/05)
     
  716. EASL: Pegasys for HBV, 72 Weeks: HBsAgSeroconversion Response (04/26/05)
     
  717. EASL: SUSTAINED RESPONSE TO PEGASYS IN HBeAg-NEGATIVE CHRONIC HEPATITIS B. (04/25/04)
     
  718. EASL: Adefovir Resistance report: 4 years update (04/22/05)
     
  719. EASL: Adefovir Week 144 Efficacy in HBeAg+ (04/20/05)
     
  720. EASL: HBV: Entecavir Compared to Adefovir & Lamivudine (04/20/05)
     
  721. EASL: Valtorcitabine (LdC) New HBV Drug Phase I/II Study Results (04/19/05)
     
  722. EASL: PegIFN+Adefovir Combination for HBV: cccDNA, seroconversion (04/19/05)
     
  723. EASL:Adefovir HBV Resistance Update (04/15/05)
     
  724. Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection - (04/14/05)
     
  725. Dual hepatitis B virus and hepatitis C virus infection: To treat or not to treat, and how? EDITORIAL - (04/09/05)
     
  726. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort (04/06/05)
     
  727. HBV DNA Can Persist After HBsAgSeroconversion (04/05/05)
     
  728. Hepatitis B or hepatitis C and HIV (04/05/05)
     
  729. Occult Hepatitis B May Progress to Cirrhosis & Liver Cancer Editorial (04/05/05)
     
  730. 1st Study of Occult Hepatitis B prevalence in Community Setting (04/05/05)
     
  731. FDA Approves New Treatment Baraclude (entecavir) for Chronic Hepatitis B (03/31/05)
     
  732. FDA Antiviral Drug Advisory Committee Recommends Unanymously to Approve Entecavir for Hepatitis B (03/15/05)
     
  733. ART May Reconstitute HBV Immunity (03/15/05)
     
  734. Disease Status & Therapeutic End Points in Hepatitis B (03/09/05)
     
  735. CROI: "Entecavir in HIV/HBV Co-Infected Patients: Safety and Efficacy in a Phase II Study (ETV-038)" - (03/08/05)
     
  736. CROI: Tenofovir for HBV/HIV Coinfection - (03/03/05)
     
  737. PegIntron+Lamivudine vs LAM for HBV - (03/01/05)
     
  738. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel - (02/24/05)
     
  739. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA - (02/16/05)
     
  740. Hepatitis B or Hepatitis C and HIV-infection Diagnosis/Care/Treatent - (02/11/05)
     
  741. Study Finds Interferon Reduces Cancer Risk in HCV+ Cirrhotics - (02/10/05)
     
  742. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance - (02/10/05)
     
  743. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma (liver cancer) - (02/09/05)
     
  744. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B - (02/09/05)
     
  745. Liver & Kidney Transplant in HIV Study - (02/03/05)
     
  746. Chronic Hepatitis B & HIV/HBV Coinfection - (01/31/05)
     
  747. Hepatitis New Drug Research - (01/26/05)
     
  748. Pegasys Receives Positive Opinion for HBV in Europe; HBV/HIV Coinfection Medical Management - (01/24/05)
     
  749. The potential of RNA interference as a tool in the management of viral hepatitis - (01/13/05)
     
  750. PegIntron with or without 3TC for Hepatitis B Treatment - (01/07/05)
     
  751. Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Epidemiology, Natural History, and Treatment - (12/30/05)
     
  752. Medicinal Herbs for HCV (oxymatrin) - (12/30/05)
     
  753. PEGASYS Approved for Chronic Hepatitis B in Switzerland - (12/28/05)
     
  754. Management of hepatitis B patients with antiviral resistance - (12/21/05)
     
  755. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment - (12/15/05)
     
  756. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination - (12/13/05)
     
  757. AASLD: Entecavir Resistance - (11/16/05)
     
  758. AASLD: LB80380, new HBV Drug - (11/15/05)
     
  759. AASLD: PegIFN for HBV, HDV, & HCV - (11/10/05)
     
  760. AASLD: ADEFOVIR FOR HBV- 144 WEEK FOLLOW-UP - (11/10/05)
     
  761. AASLD: CLINICAL PHARMACOKINETICS OF TELBIVUDINE, A POTENT ANTIVIRAL FOR HEPATITIS B, IN SUBJECTS WITH IMPAIRED HEPATIC OR RENAL FUNCTION - (11/09/05)
     
  762. AASLD: LdT & HBV Therapy Viral Dynamics - (11/09/05)
     
  763. AASLD: LdC, new HBV Drug: 4-week Dosing, Safety & Antiviral Efficacy Study - (11/08/05)
     
  764. AASLD: Remofovir, new HBV drug: prodrug of PMEA - (11/08/05)
     
  765. AASLD: Clevudine, new HBV drug, 3 studies - (11/08/05)
     
  766. AASLD: FTC for HBV - (11/08/05)
     
  767. AASLD: LdT, new HBV Drug: week 52 phase II results; Viral Dynamics - (11/08/05)
     
  768. AASLD: In Vitro Cross-Resistance HBV Drugs - (11/08/05)
     
  769. AASLD: Pegasys+Lamivudine, Pegasys, or Lamivudine for HBV Therapy - (11/05/05)
     
  770. AASLD: Entecavir in Lamivduine Experienced Patients - (11/05/05)
     
  771. AASLD: Entecavir: new HBV drug, phase III study in nucleoside-naïve HBeAg-negative patients - (11/02/05)
     
  772. AASLD: Entecavir: new hepatitis B drug-phase III study results of 48-weeks therapy in HBeAg+ nucleoside-naïve patients - (11/01/05)
     
  773. AASLD: Report 1 on Hepatitis B at the Liver Conference AASLD - (11/01/05)
     
  774. Review article: current management of chronic hepatitis B - (10/25/05)
     
  775. Occult hepatitis B in HCV+ - (10/25/05)
     
  776. High Prevalence of HBV in HIV+ & HIV- Women -WIHS - (10/21/05)
     
  777. Treatments for Hepatitis B - (10/19/05)
     
  778. Occult HBV Seen in 26% of HCV+ - (10/14/05)
     
  779. Prevention of (HBV) Hepatocellular Carcinoma - (10/08/05)
     
  780. Lamivudine Reduced Risk of Hepatic Decompensation & Liver Cancer by Half - (10/08/05)
     
  781. Valeant Pharmaceuticals to Present New HBV Drug Remofovir Pharmacokinetic and Pharmacodynamic Data From Phase 1 Clinical Trial - (10/07/05)
     
  782. Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B - (10/07/05)
     
  783. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study - (10/05/05)
     
  784. Entecavir, New Hep B Drug, BMS Files NDA with FDA - (10/05/05)
     
  785. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine - (09/30/05)
     
  786. Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? - (09/30/05)
     
  787. Genotype C HBV-infection is associated with an increased risk of hepatocellular carcinoma - (09/29/05)
     
  788. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures - (09/28/05)
     
  789. Hepatitis B virus genotype C linked to increased hepatocellular carcinoma risk - (09/24/05)
     
  790. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance - (09/22/05)
     
  791. Combination Therapy in HBV: will it improve response? - (09/22/05)
     
  792. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B - (09/22/05)
     
  793. HBV/HIV Coinfection Medical Management - (09/20/05)
     
  794. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B - (09/16/05)
     
  795. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients - (09/03/05)
     
  796. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection - (09/03/05)
     
  797. Risk of HIV & Hepatitis Infections From Blood & Tissue Donors - (08/25/05)
     
  798. Outcome of liver transplantation for hepatitis B in the United States - (08/09/05)
     
  799. HEPATITIS B IN CORRECTIONAL FACILITIES: hi prevalence & successful vaccination programs - (08/09/05)
     
  800. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR - (08/09/05)
     
  801. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B - (08/05/05)
     
  802. Roche Files for Application with FDA to Market Pegasys for Chronic Hepatitis B Treatment - (07/22/05)
     
  803. XV International AIDS Conference in Bangkok: Adefovir for HBV/HIV Coinfection with 3TC Resistance: 4 years followup - (07/19/05)
     
  804. FDA UPDATE ON VIREAD (TENOFOVIR) LABEL - (07/06/05)
     
  805. Hepatitis B Transmission in Prisons: sharing needles, sex, mother-to-child, vaccine for prevention - (07/06/05)
     
  806. Isolated Presence of Antibody to Hepatitis B Core Antigen in Patients Coinfected With HIV - (06/30/05)
     
  807. Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy--Naive and --Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus - (06/28/05)
     
  808. Long-term benefit of interferon therapy of chronic hepatitis D: regression of advanced hepatic fibrosis - (06/22/05)
     
  809. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy - (06/22/05)
     
  810. Occult Hepatitis B in HIV-Infected Patients - (06/22/05)
     
  811. DDW: Significant and Sustained Efficacy of Adefovir After 4 Years of Treatment in Chronic HBV Patients with Lamivudine-Resistant HBV and HIV Coinfection - (05/25/05)
     
  812. DDW: Three year Results from a Double-Blind, Randomized, Pacebo-Controlled, Study of Adefovir (ADV) in HBeAg-negative Chronic Hepatitis B (CHB) - (05/25/05)
     
  813. DDW: Combination of Pegylated IFN and Lamivudine is superior to Lamivudine alone in the treatment of HBV - (05/24/05)
     
  814. DDW: ADEFOVIR RESISTANCE REPORT - (05/20/05)
     
  815. DDW: Adefovir Reduced HBV Viral Reservoir & HBsAgin Parallel - (05/20/05)
     
  816. Occult HBV: Clinical Significance of Hepatitis B Core Antibody Positivity in HCV-Infected and HCV/HIV Coinfected Individuals - (05/10/05)
     
  817. HBV/HIV Coinfection & Tenofovir - (05/10/05)
     
  818. EASL: The Long-Term Outcome of HBeAg-negative Patients with Cirrhosis Treated with Lamivudine Monotherapy: a 5 year prospective cohort - (04/27/05)
     
  819. EASL: Long-Term Incidence of Adefovir Resistance in Chronic Hepatitis B Patients after 144 weeks of Therapy - (04/27/05)
     
  820. EASL: DURABILITY OF HBeAg SEROCONVERSION AFTER ADEFOVIR DIPIVOXIL TREATMENT FOR CHRONIC HEPATITIS B - (04/27/05)
     
  821. EASL: Adefovir 3 Year Study Results in Presumed Precore Mutant Chronic Hepatitis B: safety and efficacy - (04/27/05)
     
  822. EASL: HBsAgSeroconversion in Adefovir Treated Chronic Hepatitis B Patients - (04/26/05)
     
  823. EASL: Entecavir Resistance in Lamivudine Resistant Patients - (04/26/05)
     
  824. EASL: Results of a 1-Year International Phase IIB Trial of LdT, and LdT plus Lamivudine, in Patients with Chronic Hepatitis B - (04/26/05)
     
  825. EASL: EASL Hepatitis B Report 2: Pegasys Study in Hepatitis B - (04/22/05)
     
  826. Hepatitis A - (04/05/05)
     
  827. HBV Epidemiology - (04/02/05)
     
  828. Interferon for HBV Can Increase Survival & Risk for Developing Liver Cancer: study authors recommend interferon as first-line therapy - (04/02/05)
     
  829. CROI: Quantification of Hepatitis B Virus-specific T-cell Responses in HIV/HBV Co-infected Individuals - (03/15/05)
     
  830. Hepatitis B: Treatment Strategies for Currently Available Drugs - (03/08/05)
     
  831. CROI: Tenofovir is Effective Against HBV in HBV/HIV Coinfection - (03/03/05)
     
  832. CROI: Hepatitis B Treatment Update - Nancy Shulman, MD, Stanford University (03/02/05)
     
  833. CROI: Three Year Treatment with Adefovir in Chronic Hepatitis B Patients with Lamivudine (3TC) Resistant HBV and HIV Coinfection Results in Significant and Sustained Clinical Improvement - (03/02/05)
     
  834. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States - (02/05/05)
     
  835. HEP DART: Differences between Hepatitis B and C in the Prediction of Success of Treatment Using Early Viral Kinetics - (01/26/05)
     
  836. HEP DART: Clinical Development of Entecavir for the Treatment of Chronic Hepatitis B - (01/26/05)
     
  837. HEP DART: L-Thymidine (LdT) and Related Compounds - (01/26/05)
     
  838. HEP DART: A 12 Week Randomized Placebo-Controlled Double Blind Trial of Clevudine in Patients with Chronic Hepatitis B with Post-Treatment Follow-up for 24 weeks - (01/26/05)
     
  839. HHV-8 seropositivity linked with prostate cancer - (01/26/05)
     
  840. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B - (01/15/05)
     
  841. EDITORIAL: Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? - (01/15/05)
     
  842. EDITORIAL: Rescue therapy for drug resistant hepatitis B: Another argument for combination chemotherapy? - (01/15/05)
     
  843. Viral features of lamivudine resistant hepatitis B genotypes A and D - (01/14/05)
     
  844. High prevalence of occult hepatitis B in Baltimore injection drug users - (01/14/05)
     
  845. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection - (01/14/05)
     
  846. Viral features of lamivudine resistant hepatitis B genotypes A and D - (01/14/05)
     
  847. Oral feeding of hepatitis B proteins a promising treatment for chronic infection - (01/05/05)
     
  848. Hepatitis B Rates in the United States - (01/05/05)
     
  849. Incidence of Acute Hepatitis B - United States, 1990-2002 - (01/05/05)